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Cerebrovascular disease involves various medical disorders that obstruct brain blood 
vessels or deteriorate cerebral circulation, resulting in ischemic or hemorrhagic stroke. 
Platinum coils with or without biological modification have become routine 
embolization devices in the cerebral aneurysm sac to reduce the risk of bleeding. Many 
intracranial stents, flow diverters and stent retrievers have been invented with uniquely 
designed structures. To accelerate the translation of these devices into clinical usage, 
an in-depth understanding of the mechanical and material performance of these metal-
based devices is critical. However, considering the more distal location and tortuous 
anatomic characteristics of cerebral arteries, present devices still risk failing to arrive 
at target lesions. Consequently, more flexible endovascular devices and novel designs 
are under urgent demand to overcome the deficiencies of existing devices. Herein, we 
discuss the pros and cons of the current structural designs when these devices are 
applied to the treatment of diseases ranging broadly from hemorrhages to ischemic 
strokes, in order to encourage further development of such kind of devices and 
investigation of their use in the clinic. Moreover, novel biodegradable materials and 
drug elution techniques, and the design, safety and efficacy of personalized devices for 
further clinical applications in cerebral vasculature are discussed.  
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Cerebrovascular diseases have been ranked the second leading cause of death after 
ischemic heart disease in a recent analysis of the burden of 135 diseases[1]. In 2015, 
cerebrovascular diseases accounted for 6.2 million deaths worldwide, or 11.1 % of all 
deaths[2]. Cerebrovascular diseases can damage the brain by causing changes to its 
blood supply, thereby depriving brain cells of the oxygen they need for survival. The 
pathological basis for stroke is disturbance of cerebral blood circulation, which may 
either be ischemic or hemorrhagic in nature. Approximately 85% of strokes are 
ischemic in nature, leading to infarction of the tissue supplied by the occluded vessel[3]. 
Hemorrhagic stroke is mostly caused by hypertension, intracranial aneurysms due to 
widening and weakening of an artery, and vascular malformations such as tangled 
vessels. Although they account for only 13% of total strokes[4], hemorrhagic strokes are 
responsible for about 40% of all stroke mortality[5]. In the past, open surgery might be 
the only option for cerebrovascular diseases and was mainly considered for hemorrhage 
related diseases but rarely applied in acute or chronic ischemic stroke due to the high 
risk of mortality and morbidity from this operation.  
In 1971, Serbinenko pioneered endovascular therapy by using a detachable balloon 
to occlude a traumatic carotid cavernous fistula[6]. Another milestone was marked by 
Guglielmi’s report of the neurointerventional approach for cerebrovascular disease 
treatment in 1991[7]. Later on, this proof-of-concept was further commercialized into 
an electrolytically detachable platinum coil apparatus (GDC, Boston Scientific). At 
present, endovascular treatment is of utmost importance for cerebrovascular diseases 
due to its minimal invasiveness and largely satisfactory outcomes. The success of 
endovascular treatment relies heavily on the device applied since any deficiency in the 
device can cause serious consequences in the clinic. Compared with peripheral vascular 
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follows: first, the materials used must be approved for endovascular implantation and 
should not cause any bio-toxicity to neuro cells; second, the devices are required to 
have excellent flexibility and mechanical performance to avoid any hemorrhaging or 
ischemic complications during their delivery or release. Cerebral devices are often 
introduced from the femoral artery and passed through the aortic and cervical arteries 
before entering the brain vasculature; therefore, flexibility is often the first 
consideration when developing a new cerebral device. Moreover, the diameter of 
intracranial arteries is only several millimeters wide and these arteries often pass 
through the bone channel at the skull base to form an extremely tortuous path. Although 
many metal alloys, ceramics and biopolymer materials have been approved for 
implantation in a human body, only a few metals or metal alloys meet the requirements 
of cerebrovascular devices, including platinum, nitinol alloy, Co alloy and 316L 
stainless alloy [8]. Besides liquid embolic agents such as ethylene vinyl alcohol 
copolymer (Onyx), almost all intracranial implanted devices used in clinical settings 
are metal-based. Thus, the development of intracranial devices has mainly focused on 
designing novel structures. 
Intracranial implanted metal devices are roughly categorized into four sub-types: 
embolic devices (coils), stents, flow diverting devices and stent retrievers. As embolic 
devices are mostly used for aneurysm embolization, which requires excellent flexibility, 
the coils are typically made of platinum and their alloys are usually precontoured into 
a 2D or 3D shape to reduce the risk of aneurysm rupture during embolization[9]. For 
devices that need to provide intraluminal support, including stents, flow diverters or 
stent retrievers, a high compression rate is often needed to achieve a smaller profile for 
smooth delivery and good mechanical radial force is demanded to adapt to tortuous 
vessel wall after releasement. (Figure 1) Such devices are mainly made of nitinol, Co 
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can be delivered via standard catheter delivery systems, while Co and 316L stainless 
alloys cannot expand by themselves thus need a balloon catheter to dilate. 
In this review, we provide an overview of metal device usage as a minimally 
invasive treatment option for cerebrovascular diseases and discuss the advantages and 
disadvantages of their structural designs when they are applied in diseases ranging from 
aneurysms and acute stroke to chronic cerebral vascular stenosis. 
 
Figure 1. Diagram for metal devices used to treat cerebral vascular diseases[10]. 
 
2. Coil devices 
2.1 Overview 
Coils with either detachable or free designs were the first devices made of metal 
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commonly used metals are, in order of increasing hardness, nitinol, platinum, nickel, 
iridium, and tungsten; these metals all have a proven record for patient safety and their 
alloys can be used to tune the mechanical properties. To create coils for aneurysm sac 
embolization, metal stock wires are precontoured into a 2D or 3D shape. In 1991, the 
first reported electrolytically detachable coils by Guglielmi (GDC, Boston Scientific) 
were platinum coils[7]; however, a platinum (92%)/tungsten (8%) alloy has since 
become the most popular material for coil design. Platinum-based materials are used in 
a variety of medical applications, because the chemical, physical and mechanical 
stability of platinum and its alloys make them ideal for permanent implantation in the 
body. They are inert and do not corrode in physiological environments or cause allergic 
reactions, unlike other metals such as nickel and copper. Since coils used in brain 
vasculature are tiny (a few millimeters wide) and have complicated multi-dimensional 
structures, only platinum and its alloys meet the requirements. Platinum rods or wires 
can be produced in sizes ranging from 0.125" (3.175 mm) in diameter all the way down 
to 0.001" (0.0254 mm)[11], while other metal alloys, such as Nitinol alloy, cannot be 
made into such tiny diameters while maintaining a similar mechanical strength. Another 
benefit of platinum is its radiopacity; being clearly visible in X-ray images is useful for 
coil insertion, adjustment or detachment during operation. Intracranial platinum coils 
are mainly used for embolization of cerebrovascular diseases such as aneurysms and 
arteriovenous fistulas. Because of the fragile nature of vessel walls under disease 
conditions and the tortuous shape of brain arteries, the embolic system must be soft and 
flexible enough to conform to the size and shape of the aneurysm sac yet minimize 
increases in intraluminal pressure to avoid aneurysm rupture. Meanwhile, the coil 
device should also have enough stiffness, acceptable packing density and a reasonable 
three-dimensional architecture to resist stress caused by blood flow, which may cause 
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to clotting within the aneurysm sac during the initial adjustment period and have good 
biocompatibility for permanent implantation.  
The platinum coil’s configuration determines its ability to form a basket in the 
aneurysm sac and its packability, which can be predicted from its primary, secondary 
and tertiary structures. The primary structure is the “stock” wire with a diameter (D1) 
that is usually between 0.00175 and 0.003 inch. It is wound around a mandrel to create 
the coiled secondary structure, which may vary in size along its length. The secondary 
structure diameter, D2, can range from approximately 0.010 inch to 0.015 inch
[8b]. 
Finally, the secondary structure can be shaped into tertiary configurations, such as 
helices, spheres, and complex or irregular 3D structures, described by a particular loop 
diameter (D3) and length (L). 
In the clinic, the coil stiffness and configuration are two fundamental considerations 
for coil selection from among the commercially available systems. During an 
embolization procedure, coils will be inserted until the aneurysm sac is sufficiently 
occluded; operators choose specific stiffnesses and configurations of coils to perform 
framing, packing and wind up. Stiffness is a critical determinant of a coil’s mechanical 
strength and is directly related to the material properties as well as the coil structure. 
The metal strength is described by the shear modulus (G) of the stock wire (Equation 
1), defined as the ratio of the shear stress to the shear strain[8b], which describes the 
coefficient of elasticity under a shearing force. A thinner stock wire diameter (D1) will 
make a softer coil while the secondary structure diameter (D2) and the spacing between 
turns influence both stiffness and packing. Lastly, the tertiary parameters (D3 and L) 
are key determinants of the entire system’s effective stiffness and commercial products 
are often differentiated at this level. Since a softer coil will demonstrate improved 







































































Equation 1. Coil stiffness equation 
Complex or spherical coils with a 3D structure are the most frequently selected as 
the first coil to construct a frame to allow further insertion of embolization coils. The 
3D framing coils can be divided into stable and unstable shapes. A 3D coil with a stable 
shape will keep its precontoured shape inside the aneurysm sac to allow more coils to 
be inserted in the future. Commercially available examples of such coils include the 
Guglielmi detachable coil (GDC) 3D (Stryker), Orbit (Codman Neurovascular), Micrus 
Presidio (Codman Neurovascular) and Target 360 (Stryker) coils. A 3D coil with an 
unstable shape has better flexibility and its precontoured 3D shape can be adjusted to 
irregular sacs, as demonstrated by products such as Cosmos (MicroVention/Terumo, 
Inc.; Aliso Viejo, Calif), Axium (Covidien/ev3) and Target nano 360 (Stryker) coils. 
The Target Nano (Stryker), Delta Plush (Codman Neurovascular) and Axium Prime 
(Covidien/ev3) are 2D coils with a helical shape that are primarily used for 
embolization. Some ultrasoft coils with small diameters are specifically designed to 
perform embolization as the last or finishing coil, such as the VFC 
(MicroVention/Terumo), Target Nano (Stryker) and Axium Prime (Covidien/ev3). 
Meanwhile, many kinds of modified coils have been developed to improve embolism 
outcomes by promoting blood coagulation or by enabling increased packing densities; 
these include polyglycolic acid (PGA)-core coils, polylactic-co-glycolic acid (PLGA) 
coated coils, coils with PGLA or nylon fibers attached or expandable hydrogel coils, 
which are also called “bioactive coils” [8b] (Figure 2) (Table 1). 
To perform an embolism treatment, a coil is delivered through the lumen of a 
microcatheter to the target lesion via a push wire. There are many kinds of 
microcatheters that can be used for coil system delivery. Typically, they have inner 
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microcatheter does not always mean that the coil will pass through more smoothly. In 
fact, a mis-matched bigger catheter lumen is likely to cause the pre-shaped coil to 
buckle, therefore preventing the pushing force from being transmitted along its axis. 
This may increase friction between the coil and the catheter wall, and cause 
uncontrollable coiling within the aneurysm. Presently available coils use three types of 
detachment methods: 1) electrolytic detachment; 2) hydraulic detachment and 3) 
mechanical detachment. The principle of electrolytic detachment, which was first 
applied by Guglielmi, is to use an electric current to melt the metallic connection 
between the coil and the delivery wire to achieve coil detachment. The primary 
advantage of this detachment method is that the metal connection between coil and the 
push wire makes it firm. However, sometimes electrolytic detachment may require 
repeated attempts, so the detachment time can range from a few seconds to several 
minutes. Moreover, detachment of the Guglielmi coil resulted in gas generation and 
increased risk of clot formation[12]. Hydraulic detachment and mechanical detachment 
are newer methods and are superior to electrolytic detachment because there is no metal 
at the connection between the coil and the push wire, which may not increase the 
stiffness of the whole coil system. More importantly, the more consistent seconds-long 
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Figure 2. Structure design of platinum coils. Two-dimensional and three-dimensional 
platinum coils can be applied for aneurysm sac embolism (a) and a typical three-
dimensional platinum coil (b) configuration from a primary (1°) to secondary (2°) to 
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Ultipaq and Helipaq two-
dimensional filling coils 
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2.2 Typical coils 
2.2.1 Axium™ coils 
The Axium™ detachable coil system consists of a tertiary structure coil and a delivery 
system. The coil is constructed of a platinum/tungsten alloy primary line, a 
polypropylene core wire and a 316L stainless detachable zone. The coil system sizes 
range from the largest (25 mm) to the smallest (1.5 mm) available 3D helices. The coil 
design aims to balance the softness of a size “10” serial coil with the stability and 
volume of an “18” serial coil. All Axium™ coils are mechanically detached by a simple 
push movement that separates the link from coils’ body without any cables, boxes or 
batteries. This detachment method is fast and facilitates precise coil placement, both of 
which are especially important when treating a ruptured aneurysm. 
Axium™ coils include bare platinum coils, PGLA microfilament coils, and nylon 
microfilament coils in stiffnesses from soft to super soft. In most coil sizes, various 2D 
helix shapes and 3D tertiary shapes are available for clinical selection. The 3D Axium™ 
has large loops which can change packing direction when they touch the aneurysm wall; 
this design makes the coil adapt well to irregular sacs and provides good mechanical 
stability for subsequent insertion of 2D coils. The Axium™ Prime (Super Soft) coil (44% 
thinner primary wire, 38% thinner stretch-resistant strands) is four times softer than the 
routine Axium bare coils, enabling the coils to better conform to the aneurysm shape 
and fill in open spaces. Axium™ MicroFX™ coils have additional overlapped nylon or 
PGLA microfilaments between coil loops, which are both procoagulant materials that 
prompt thrombosis inside the aneurysm sac to further reduce the risk of aneurysm 
bleeding or recurrence [22, 24]. PLGA is a bio-absorbable material and nylon is a more 
durable but non-absorbable material, so the overlapped design creates a more 
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2.2.2 Target® coils 
The Target® detachable coil is a new generation bare coil from the Stryker Company; 
it is an update from the first generation GDC coil. The Target® coil has a laser-ablated 
detachment zone that uses 82% less metal and can be detached more quickly than GDC 
(around 30 seconds compared with minutes). Less metal between the coil and push wire 
makes the connection zone shorter and softer, which minimizes microcatheter kickback 
and enhances stability during coiling. 
The Target® detachable coil family includes Target® XL, Target® 3D, Target® 360 and 
Target® Nano coils. The Target® XL and 3D are used for regular embolization; the 360 
is designed especially for frame building and Nano coils are optimized to be the last 
coil during embolization[25]. The first 1.5 loops of the Target® 360˚ coil are 25% smaller 
than the specified secondary coil diameter, which allows the first few loops to roll freely 
within the aneurysm sac to adhere to the outer wall and leave an open center, making it 
suitable for further filling and neck coverage using concentric coils[26]. The Nano™ 
detachable coil is softer than most coils with a diameter <2mm and 2 times softer than 
normal Target ultrasoft coils. It is constructed by using a smaller primary wire and the 
most flexible delivery wire. The increased conformability of Nano™ coils is designed 
to treat challenging, small aneurysms or residual spaces after coilingh[27]. The Nano™ 
coils come in two shapes, Target® 360 Nano™ coils and Target® Helical Nano™ coils, 
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2.2.3 Hydrogel Coils 
Hydrogel coils were developed to improve packing density by using an expansible 
hydrogel that is more effective at filling the aneurysm lumen compared to bare platinum 
coils. Examples of hydrogel coils include the HydroCoil® Embolic system, the 
HydroSoft® and HydroFrame® Advanced Embolic coils and the HydroFill® Advanced 
Embolic coil. 
The HydroCoil® Embolic System is the first generation of hydrogel coils. The device 
has a platinum coil base with a synthetic, polymeric hydrogel attached to the surface. 
The hydrogel swells to a nine-fold increase in volume in a physiological environment[28]. 
The initial diameter of these devices is approximately 0.010 inches, which is compatible 
with the 0.017 inch inner diameter of microcatheters. The hydrogel coating will 
significantly expand after only 5 minutes, thus the HydroCoil needs to be deployed or 
retracted back into the microcatheter within this period of time. In blood, the hydrogel 
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HydroSoft® and HydroFrame® Advanced Embolic Coils belong to the new generation 
of the HydroCoil® Embolic System. Both of these coils have a hydrogel core inside an 
outer platinum coil. Due to a 2D helical shape and ultra-soft stiffness, the HydroSoft® 
coil seeks out small spaces and delivers hydrogel at the aneurysm neck to improve 
aneurysm sac occlusion and reduce aneurysm recurrence rates as compared to bare 
platinum coils[29]. HydroFrame® has variable diameter loops to facilitate the formation 
of a frame in irregularly shaped aneurysms[30]. Hydrogel coils at the aneurysm neck are 
more likely to increase the neck coverage than bare coils. In addition, the expanded 
hydrogel can provide extra scaffolding to facilitate neointima formation across the neck 
to prompt histological healing. As a result of the new design, the second-generation 
coils need no prepping or steaming before usage and have an extended 30-minute 
working time. Both kinds of new coil systems are compatible with 0.0165" to 0.021" 
inner diameter microcatheters. 
The HydroFill® Advanced Embolic coil is designed for volumetric filling of aneurysm 
sac and can reduce intra-aneurysm flow using fewer coils than bare coils[31]. In 
experimental aneurysms created to test the occlusion effect of HydroFill, the hydrogel 
material swelled through the platinum coil and expanded the diameter by 20%, 
increasing volumetric occlusion compared with a bare platinum coil[32]. Similar to bare 
platinum coils, HydroSoft® and HydroFrame®, a HydroFill® coil does not need to be 
steamed prior to working and has a reasonable 10-30 minute working time for coil 
insertion and adjustment.  
2.3 Clinical applications 
Metal coils are always the first choice in the clinic for endovascular embolization 
of aneurysm sacs because they reduce the risk of subarachnoid hemorrhaging caused 
by a ruptured aneurysm, a serious complication that results in a nearly 50% mortality 
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necessary to rationalize the choice of devices for better treatment outcomes and to 
reduce complications. Meanwhile, other devices such as balloons and stents are also 
widely used in conjunction with coils to facilitate and increase the coil packing rate, 
reduce coil herniation and maintain parent artery patency. A thorough understanding of 
the feasibility, efficacy and safety of these assisting techniques may guide the 
practitioner in their treatment approach during clinical application.  
2.3.1 Endovascular coiling for cerebral aneurysm 
The development of coils with very controlled detachment systems is crucial for their 
widespread use in endovascular treatments[7, 33]. Despite the fact that coils have also 
been used successfully for cerebrovascular diseases such as direct arteriovenous fistulas, 
dural arteriovenous fistulas and arteriovenous malformations, coils are most widely 
used for aneurysm embolization in the clinic. The International Subarachnoid 
Aneurysm Trial (ISAT) revealed that endovascular coiling treatment has a more 
favorable early survival advantage as well as lower morbidity and mortality rates than 
surgical clipping, which tries to cut off blood flow to the aneurysm by inserting a metal 
clip at the aneurysm neck[34]. Large studies from single or multiple centers showed 
acceptable mortality (≈2%) and morbidity rates (between 4% and 9%) after coiling 
treatments, most of which were related to thromboembolic complications and 
intraoperative rupture[35]. Due to the development of noninvasive imaging techniques, 
increasing numbers of intracranial aneurysms diagnosed before rupture are able to 
receive coiling treatments. In the first prospective multicenter study, Analysis of 
Treatment by Endovascular approach of Nonruptured Aneurysms (ATENA), a total of 
739 coiled unruptured aneurysms yielded a technique success rate of 95.7%, technical 
adverse event rate of 15.4%, 1-month morbidity rate of 1.7% and 1-month mortality 
rate of 1.4%[36]. The results of the prospective ISUIA study also indicate a better 
outcome associated with coiled aneurysms[37]. Thus, coiling for aneurysms, whether 
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With the development of more flexible, shaped and bio-material coated coils, 
endovascular coiling treatment outcomes are consistently improving. The final 
treatment outcome may depend on many factors including coil size, stiffness, 
configuration, surface modification techniques and most importantly, the doctor’s 
experience with the principles of coil selection. Packing density, defined as the ratio of 
the inserted coil volume to the total aneurysm volume, can also affect aneurysm 
recurrence rate observed during angiographic follow up. To achieve a higher packing 
density, the inserted coil volume, which is dependent on both coil thickness and length, 
must be increased. Theoretically, thicker coils should have a higher packing density 
than thinner ones of the same length[38]. 
2.3.2 Treatment outcomes using modified coils 
Many modified coils have been developed to increase the coil packing rate, clot 
formation or inflammatory response within the aneurysm sac to promote mechanical or 
histological healing of an aneurysm. Typical surface-modified coils include the 
HydroCoils, Axium MicroFX, Micrus Cerecyte and Matrix coils. Modification 
techniques include coating with a hydrogel or PGLA, or microfiber attachment. 
Applying these techniques on bare coils can reduce the risk of aneurysm recurrence, 
rebleeding, and the need for retreatment.  
The HydroCoil embolic system obviously improves the packing rate in the aneurysm 
lumen, 72% as compared to 32% with standard platinum coils[39]. In the HydroCoil for 
Endovascular Aneurysm Occlusion (HEAL) Study, the recurrence rate after coiling was 
0% when HydroCoil represented ≥75% of the total coil length compared with a 
recurrence rate of 23% when <75% of the length was HydroCoil (P = .035). Similarly, 
when the final coil inserted was a HydroCoil, the recurrence rate was 11%, considerably 
lower than the 29% recurrence rate when the final coil was a bare platinum coil (P 
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the aneurysm sac and the aneurysm neck to reduce recurrence. However, some concerns 
remain when using HydroCoil at the aneurysm neck as the swelled hydrogel may 
herniate into the parent artery and result in stenosis or occlusion. Even so, the further 
randomized HydroCoil Endovascular Aneurysm Occlusion and Packing Study (HELPS) 
trial revealed that using hydrogel coils gave an absolute 7.0% reduction in the 
proportion of major aneurysm recurrence at 18 months after treatment (28% vs. 36% 
for the control patients), which indicated hydrogel coils were more effective than bare 
coils. Possible reasons for the reduction may be that hydrogel coils reduce the number 
of coils necessary, and thus, the procedure time. In patients with recently ruptured 
aneurysms, the hydrogel group had 8.6% fewer major angiographic recurrences than 
the control group, suggesting improved adverse primary outcomes[41]. The German 
Randomized Endovascular Aneurysm Trial (GREAT) was conducted to compare 
HydroSoft/HydroFrame coils with standard platinum coils and the results also indicated 
higher packing densities with hydrogel coils while complication and angiographic 
occlusion rates were the same for both two groups[30, 42]. In the Axium MicroFX for 
Endovascular Repair of IntraCranial Aneurysm (AMERICA) study, 100 aneurysms 
were treated with Axium MicroFX Coils. The total technical success was 99%, and 
90.6% of the aneurysms with follow-up data had Raymond grade I (complete) or II 
(residual neck only) occlusion[22, 43]. 
Despite indications that hydrogel coils and nylon or PGLA microfilament coils 
should yield more favorable treatment outcomes than bare platinum coils, clinical trials 
have so far revealed results to the contrary. Kang et al. found that even though the mean 
coil volume deployed and packing density were notably higher when PGLA coils 
(Matrix coil, Boston Scientific) were used, the incidence of recanalization was the same 
as for bare coils[44]. Similar results were also observed for Cerecyte (Micrus 
Endovascular, San Jose, CA, USA) coils during a 6-month angiographic follow-up[23]. 
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overall benefit over the standard platinum coils[45]. We believe that reasons for these 
disappointing results may include: 1) only a few randomized clinical trials have been 
conducted on this topic, and bias arises from the fact that aneurysms treated using 
bioactive coils are mostly complex aneurysms, such as wide-necked, large, giant or 
dissecting aneurysms, which are more challenging to treat than typical cases; 2) no 
principle of selection for bioactive or bare coils was strictly defined and followed by 
the different studies; and 3) as with bare coils, the experience level of the operators can 
greatly influence the final occlusion rate of the aneurysms.  
2.3.3 Balloon remodeling technical for aneurysm coiling 
For complicated cerebral aneurysms, such as wide-necked, large or giant aneurysms, 
simple coil embolization often runs a risk of low coil packing rate and incomplete neck 
occlusion, which is likely to result in residual neck/sac or aneurysm recanalization. An 
increased packing density is the key to increasing the healing rate of complicated 
cerebral aneurysms. Balloon deployment in the parent artery increases metal packing 
density to avoid recanalization caused by blood flow and can also help seal or remodel 
the aneurysm neck shape to prevent coil protrusion or herniation back into the parent 
artery.  
The balloon remodeling technique entails the temporary inflation of a balloon 
catheter during the coiling procedure. The balloon is placed in front of the aneurysm 
neck to prevent protrusion and herniation back into the parent artery and is removed at 
the end of the procedure so no device is left in the vessel[46]. The most popular balloon 
catheters for remodeling are currently the HyperGlide™/HyperForm™, which are 
compatible with a 0.010-inch microguidewire, and the Transform™ and the Septer™, 
which are both compatible with a 0.014-inch microguidewire. The Scepter balloon 
catheter allows the placement of a stent (LVIS JR stent) by inserting the stent through 
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balloon remodeling technique is that the balloon can be used as a rescue tool to 
temporarily occlude the parent artery if the aneurysm ruptures during coiling.  
In the Clinical and Anatomic Results in the Treatment of Ruptured Intracranial 
Aneurysms (CLARITY) study, two options for treating ruptured aneurysms, 
conventional coil embolization or balloon remodeling coiling, were found to have 
similar levels of safety as determined by perioperative complications and clinical 
outcomes[48]. The rates of treatment-related complications, thromboembolic events, 
intraoperative rupture, and early rebleeding were not significantly different between the 
two groups. Furthermore, the cumulative morbidity and mortality rates were similar 
(3.8% in the remodeling group vs. 5.1% in the coil embolization group). For unruptured 
aneurysms, the ATENA study found that the overall complication rate was 11.7% for 
balloon remodeling coiling and 10.8% for standard coiling. Interestingly, 
thromboembolic events occurred slightly more often in the standard coiling group than 
in the balloon remodeling coiling group (6.2% vs. 5.4%, respectively)[49]. This was also 
reported in the meta-analysis by Shapiro et al[50]. We estimate that the balloon 
remodeling technique may make coiling in aneurysm sacs smoother and significantly 
simplify the interventional manipulation, as ischemic complications are always 
believed to be proportional to the total procedure time.  
 
3. Stent devices 
3.1 Overview 
The tortuous course of the cerebrovasculature, especially at the siphon segment of 
the internal carotid artery, can form relatively sharp spatial angles. On one hand, these 
anatomic features require higher flexibility in the stent delivery system to arrive at the 
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the stent to adapt to the complex arterial wall shape after release. In addition to their 
typical use in the treatment of stenosis, stent assisted coiling (SAC) is an effective 
combination technique to stabilize coils inside the aneurysmal sac. So far, most 
clinically-available intracranial stents are bare metal stents that are made of materials 
including nickel-titanium alloys (nitinol), cobalt-based alloys and medical-grade 
stainless-steel alloys. A nitinol alloy is used to manufacture self-expandable stents 
while cobalt-based alloys and stainless-steel alloys are used for balloon expandable 
stents. Cobalt-based alloys have superior mechanical performance, such as a larger 
radial force, than stainless steel.  
Stent cell structures can be generally divided into three types of designs: open cell 
stents, closed cell stents and half-open cell stents. Each cell in a closed cell stent is fully 
enclosed by struts while open cell stents have some open-ended cells. Usually, open 
cell designs are differentiated from closed cell designs based on the number and 
arrangement of bridge connectors. A braided stent, such as the LVIS stent 
(Microvention), is a typical closed cell stent design. Its advantages include a high 
compression rate to reduce the stent profile and provide uniform radial force or dilation 
against the vessel wall, however, it also comes with increased risk of stent migration 
and reduced flexibility, high stent shortening rate, and difficult positioning during 
deployment[51]. Closed cell stents can also be made by laser cutting, such as Enterprise 
stent (Cordis), although such designs do not have as high a compression rate. In order 
to maintain sufficient flexibility, the thickness of stent struts must be reduced, which 
often indicates a sacrifice of stent radial force. Because of its design, a closed-cell stent 
has limited flexibility to conform to curved or irregular anatomies, which may cause 
the stent to flatten or kink, resulting in incomplete stent apposition and running the risk 
of higher thromboembolic complication rates[52]. Most open or half open cell stents are 
made by laser cutting. Open cell stents provide better conformability to curved vessel 
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applications However, its struts can kink in curved vessels during deployment to cause 
acute in-stent thrombosis or long term in-stent re-stetnosis. The Neuroform stent 
(Boston Scientific) and the Winspan stent (Boston Scientific) are common open cell 
stents.  
The delivery system is also very important, especially when the stent is used in 
cerebrovascular systems, as the flexibility of the whole stent system depends largely on 
the delivery system. A self-expandable nitinol alloy stent only needs a microcatheter or 
delivery sheath, while cobalt-based alloy or stainless steel stents are compressed around 
a balloon catheter and expanded during balloon dilation. The catheter delivery system 
is more flexible than a balloon catheter. Thus, most intracranial stents use this method 
to increase the chances of successfully arriving at the target: a catheter is first navigated 







































































Figure 3. Typical stents used in clinical treatment of cerebral aneurysms and 
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3.2 Typical stents 
3.2.1 NeuroformTM stent 
The NeuroformTM stent (Boston Scientific/Stryker) is a nitinol self-expanding 
intracranial device designed to prevent coil protrusion during stent-assisted coiling of 
intracranial wide-necked aneurysms. The open-cell design provides good flexibility and 
conformability. Importantly, this architecture can be expanded segmentally to promote 
stent anchoring and stability during coiling. The first three generations of NeuroformTM 
stents were pre-loaded on an enhanced stent delivery wire and sheath system, but were 
not flexible enough to be accessibly navigated in the tortuous brain vasculature. To 
improve flexibility, the NeuroformTM stent system has further undergone multiple 
iterations including the NeuroformTM 2, NeuroformTM 2 Treo, NeuroformTM 3, 
NeuroformTM EZ® and Neuroform™ Atlas stents.  
The Neuroform EZ® Stent System has a 19 mm distal radiopaque tip with similar tip 
softness as the micro guidewire used in clinic, and it has a 45 degree pre-shape to aid 
in navigation. The Neuroform EZ® Stent is pre-loaded on a 0.027 inch microcatheter 
delivery system. The stent delivery wire is a 185 cm stainless steel, with its diameter 
tapers from 0.018 inch to approximately 0.010 inch at the distal tip to increase 
flexibility and pushability. The NeuroformTM EZ® Stent System has a simplified 
delivery system that can be handled by single operator and does not require delivery 
system exchange like the NeuroformTM 3 stent system does. The deployment failure 
rate of the NeuroformTM stent is only 2.3%[62], which indicates that it is safe and 
effective for SAC applications. However, a delayed self-expansion phenomenon has 
been reported[63] during a stent-assisted coiling procedure for a ruptured intracranial 
aneurysm, possibly due to the stent unfolding inside the sheath before deployment. 
Alternatively, failure to mechanically expand can also occur the moment the stent 
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interventionists should keep it in mind, especially for small parent arteries or any other 
factors that increase the risk of unstable stent deployment. The Neuroform™ Atlas stent 
is a new generation of stent with a mixed architecture of open and closed cells. The 
closed cells at its proximal ends can facilitate re-cross of the microcatheter with its 
lumen Open cells designs in other segments promise more reliable stent opening at 
sharp bends of the parent artery resulting in good wall apposition. Meanwhile, 
alternating 8 cell and 12 structure elements can improve stent flexibility. The 
Neuroform™ Atlas stent is delivered and deployed by 0.017-inch inner lumen 
microcatheter and should be capable of assisting aneurysm embolism in distal, smaller 
or even more tortuous vessel lumens[64]. However, because the stent strut thickness is 
greatly reduced, users should monitor it for weakness of radial force and potential lower 
metal coverage rate (defined as the ratio of the surface area covered by metal to the 
total surface area) in the aneurysm neck, which results in a higher risk of aneurysm 
recanalization. 
3.2.2 WingspanTM stent 
The WingspanTM stent system (Stryker Neurovascular, Kalamazoo, Michigan) and 
GatewayTM percutaneous transluminal angioplasty (PTA) balloon catheter (Stryker 
Neurovascular, Kalamazoo, Michigan) were approved by the FDA in 2005 for patients 
with severe intracranial atherosclerotic stenosis (≥50%) for whom antiplatelet therapy 
was not effective. To use the stent system, the GatewayTM PTA balloon catheter is first 
inflated to dilate the stenotic artery, and is then followed by placement of WingspanTM 
stent within the target vessel to maintain its patency after dilation[65]. The distal tip of 
Wingspan TM inner shaft is spindle-shaped, which is helpful for it to cross the target 
lesion and draw it back within the deployed stent. The delivery line is covered with 
hydrophilic material, while its taper changes from 2.4 F (0.8mm) distally to 3.2 F 
(1.07mm) proximally to increase flexibility and safety. However, negative results about 
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Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) 
trial[66]. Thus, additional caution should be paid to its safety and the following criteria 
should be met before its intracranial insertion, according to the FDA Humanitarian 
Device Exemption documentation[67] for the Wingspan stent system: 1) patients should 
have had two or more strokes even under aggressive medical management; 2) the most 
recent stroke occurred more than seven days prior to planned treatment with Wingspan; 
3) patients should have 7099% stenosis due to atherosclerosis of the intracranial artery 
related to the recurrent strokes; and 4) patients have made good recovery from previous 
strokes and have a modified Rankin score of 3 or less prior to Wingspan treatment. 
Moreover, the Wingspan stent should not be used for patients for whom the treatment 
of stroke has an onset of symptoms within seven days or less of treatment, or for the 
treatment of transient ischemic attacks (TIAs)[66].  
3.2.3 EnterpriseTM stent 
The EnterpriseTM stent (Codman & Shurtleff) is a closed-cell, self-expanding stent 
with flared ends. This design enhances stent apposition to the vessel wall, so it is 
appropriate for the treatment of wide-necked intracranial aneurysms and stent-assisted 
coiling procedures. The EnterpriseTM stent received FDA approval for clinical usage in 
2007. So far, the Enterprise stent has been further developed into the Enterprise® 2 
vascular reconstruction device. The Enterprise® 2 is more radiopaque, making it more 
easily observed under fluoroscopes. The Enterprise stent system can be introduced by 
a standard microcatheter and recaptured or redeployed if ≤70% is deployed. The flared 
end of the Enterprise stent promotes wall apposition and conformability, as well as 
facilitates re-access though stent. The closed-cell design improves its ability to maintain 
the coil in the aneurysm and prevent it from protruding into the parent artery. Many 
studies indicate that the Enterprise stent can safely treat wide-necked aneurysms[53k, 62, 
68], but some reports mentioning post-procedure migration of an intracranial Enterprise 
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lubricated polymer, the closed-cell design, differences in outward radial force between 
the flared end and the stent body, or particular anatomic scenarios of posterior 
circulation. 
3.2.4 Leo stent  
The Leo stent (Balt, Montmorency, France) was the first braided, retrievable, and 
self-expanding stent developed for the treatment of intracranial wide-neck aneurysms. 
The Leo stent body is composed of twisted nitinol wires for high radial force and 
continuous surface coverage, and two platinum markers for visualization of both the 
stent diameter and its length. To date, the Leo stent has two product lines: Leo plus stent 
and Leo plus baby stent. The Leo plus stent consists of 16 braided wires to form dense 
mesh cells to provide good coil support. The Leo plus stent is pre-loaded onto its own 
delivery wire. Also, it is resheathable up to 90% of its deployment length, and thus, can 
be easily repositioned. Two helical markers running down the entire body of Leo plus 
stent make the full stent visible under fluoroscopy. The end of the stent is a rounded 
short flare similar to the Enterprise stent, which ensures smooth wall apposition and 
easy navigation. The Leo plus baby stent is also a self-expanding and braided stent with 
radiopaque markers on its two ends, but it has three additional radiopaque tantalum 
threads in the body. The Leo plus baby stent is compatible with a low profile 
microcatheter (0.017 inch) that allows the stent to gain access to vessels down to a 
diameter of 2 mm. However, in wider arterial lumens, the braided structure design 
decreases radial force compared to the Neurform Atlas stent and it is not suitable for 
deployment in tortuous arteries.  
3.2.5 Solitaire AB stent  
The Solitaire stent (EV3) is the only nitinol and self-expanding stent designed 
with an open slit along the axis and closed cells that is fully retrievable for stent-assisted 
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the brain. This stent is delivered through a standard 0.021 or 0.027 inch microcatheter 
using a 0.016 inch pushwire. The Solitaire stent allows for multiple retrievals and 
adjustment after full deployment, just like detachable coil manipulation. It can be 
electrolytically detached after deployment. When not detached, Solitaire stent can be 
safely held or placed without risk of migration during coil placement or balloon use. 
There are 3 or 4 radiopaque markers on the distal end of the stent and one marker on 
the proximal end for increased visibility. The overlapping curled design increases stent 
softness and allows the stent to expand in larger vessels and compress in smaller vessels 
during deployment. There is a non-working length between the working length and the 
proximal marker to facilitate stent retrieval, but this design makes the microcatheter re-
cross the stent lumen or double stent overlapping deployment becomes difficult. A 
0.021-inch microcatheter is suitable for a stent with 4 mm diameter and 0.027-inch for 
a stent with a 6 mm diameter. The overlapping, highly flexible and retrievable structure 
are reasons why the Solitaire stent has been applied to a diverse range of stent 
techniques. Besides the normal single-stent assisted coiling technique, Y-stenting and 
Kiss-stenting coiling techniques are also frequently employed using the Solitaire stent. 
One general limitation of the Solitaire stent is its low metal coverage rate, which makes 
it difficult to prevent coil protrusion and aneurysm neck healing[58c, 70]. 
3.2.6 LVIS stent 
The LVIS stent (Microvention) is a self-expandable, 16-wire, low-profile nitinol 
braid stent that can be visualized under fluoroscopy. It is intended for use in SAC 
procedures for the treatment of wide-necked and dissecting aneurysms[71]. It has a 
smaller than average cell size (0.9 mm) and approximately 23% metal coverage, which 
is much higher than normal coil-assist stents, which average between 6-8% metal 
coverage. The increased metal coverage provides better protection against coil 
protrusion and flow diversion of the parent artery to accelerate thrombosis in the 
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end in addition to dual helical strands, so it is easily-visualized throughout the 
procedure course under X-ray. The LVIS stent is compatible with 0.021 inch 
Headway® microcatheters. To improve wall apposition, conformability, and to 
facilitate stent access, the end of LVIS stent is flared, a design similar to the Enterprise 
and Leo stents. Meanwhile, the similarly-designed LVIS Junior has a 50% larger cell 
(1.5 mm) than the standard LVIS stent, which enables it to be delivered through even 
lower-profile microcatheters (0.017 inch) for parent vessels 2.0-3.5 mm in size. The 
LVIS Junior is a self-expanding Nitinol 12-wire braided device with three radiopaque 
tantalum threads within the body and radiopaque markers on each end of stent. The 
Headway®17 advanced microcatheter and scepter occlusion balloon catheter are both 
compliant with the LVIS Junior stent. As the LVIS and LVIS JR stent both have a much 
higher metal coverage rate than normal coil-assist stents, it is important to pay 
additional attention during its deployment at tortuous or bifurcated arteries, as there is 
a risk of in-stent thrombosis due to stent kinking or occlusion of the bifurcated arteries 
if it is pushed too much.   
3.2.7 ApolloTM stent 
The Apollo stent (MicroPort) is a balloon expandable stent designed for the treatment 
of intracranial artery stenosis. The support units of this open-cell stent are shaped like 
sine waves and segments are connected with asymmetrical strengthening rings to 
enhance radial strength and flexibility for navigating tortuous intracranial arteries. The 
stent is laser-cut from medical-grade 316L stainless steel with diameters between 2.0-
4.0 mm and lengths of 8 to 23 mm. The Apollo stent has a metal coverage rate between 
10.6-15.2% and strut thickness of 0.004 inch. This stent system has a 0.040 inch 
maximum crossing profile and is delivered by a 0.014 inch microwire. The relatively 
low pressure (6 atm) it needs to release decreases the likelihood of vessel tearing or 
rupture. The greatest advantages of the Apollo stent are accurate positioning during 
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improvements to improve its flexibility, this stent system is still not flexible enough for 
use in tortuous brain vasculature and the balloon dilation is likely to cause arterial wall 
damage or occasionally artery rupture.  
3.2.8 WillisTM stent graft 
The Willis covered stent or stent graft is a newer stent designed for intracranial 
vasculature applications, including the treatment of cerebral aneurysms or 
arteriovenous fistulas[10c, 61, 72]. It consists of 3 parts: a bare stent, an expandable 
polytetrafluoroethylene (ePTFE) membrane, and a low-pressure flexible balloon 
catheter. It is produced in diameters from 3 to 5 mm and in lengths from 7 to 19 mm. 
This stent system is very flexible because multiple stent bodies are connected at 2 
asymmetric points between the crest walls. The thin, tubular ePTFE membrane of the 
stent is only 30-50 μm thick, and the balloon has 5 valves (instead of 3) to prevent it 
from climbing the inner wall of the stent when withdrawing. To facilitate precise 
placement, the whole body of the stent is made of a radiopaque cobalt alloy. Similar to 
the Apollo stent, the balloon-expandable stent release method makes this stent system 
slightly stiffer and thus it can only be used in vessels with few curves and in arterial 
segments without important branches or perforators give out. 
3.3 Clinical applications 
Stent insertion can be applied directly or indirectly to the treatment of different 
cerebrovascular diseases, including hemorrhagic stroke (cerebral aneurysm) and brain 
ischemia (intracranial atherosclerotic stenosis). For cerebral aneurysms, bare stents are 
often used as an assisting tool to increase the coil packing density. The Neuroform and 
Enterprise stents are typical open-cell and closed-cell stents, respectively, with low 
metal coverage, around 10%, to facilitate coiling; in contrast, the Leo and LVIS stents 
are designed not only to facilitate coiling but also to improve coverage at the aneurysm 
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occlude the aneurysm sac while reconstructing the diseased parent artery[10c, 61]. For 
treatment of atherosclerotic stenoses, stents can be used to remodel the target vessel to 
maintain patency following balloon catheter inflation. Stents used for such procedures 
include the Wingspan and Apollo stents. Stents designed to dilate atherosclerotic 
stenotic arteries often require high radial force compared to stents designed for coiling 
assistance, which is often deployed within normal arterial lumens[74]. 
3.3.1 Stent used for aneurysm coiling assistance 
Stent assisted coiling (SAC) is an effective technique used in the treatment of wide-
necked complex aneurysms to stabilize coils inside the aneurysmal sac, which prevents 
herniation back into the parent artery. SAC has been applied to treat a wide range of 
aneurysms and it is considered a feasible technique to decrease the risk of aneurysm 
recurrence. There are two major kinds of SAC techniques: jailed coiling and trans-cell 
coiling. To apply the jailed coiling technique, a microcatheter is first inserted into the 
aneurysm sac and then the stent is semi- or fully released to jail the microcatheter while 
stent struts can seal the aneurysm neck. A great advantage of the jailed coiling technique 
is that the stent can be adjusted or re-sheathed after being partially released. 
Consequently, although any kind of stent can theoretically be used for this technique, 
most operators prefer to use re-sheathable closed-cell stents as they may also allow for 
loose jailing of the microcatheter head to enable better coiling. Frequently used jailing 
stents include laser-cut stents (the Enterprise™ and the Solitaire™ stent) and braided 
stents (the LVIS™ and the LEO™).  
Trans-cell coiling is the earliest stent assisted technique used to increase packing in 
the aneurysm sac. After the stent is deployed, the microcatheter advances into the stent 
lumen and its head goes into the aneurysm sac to perform coiling. This technique is 
more complicated to implement than the jailed technique, and often requires that stent 
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microcatheter to enter the aneurysm sac. In this situation, open-cell stents often perform 
better than closed-cell stents, especially when the parent artery is tortuous. Open-cell 
stents can cover the aneurysm neck better than closed-cell stents as they may gather 
their struts at the neck of the aneurysm and conform to the vessel curvature, which 
induces less vessel straightening. Open-cell stents typically used for the trans-cell 
coiling technique are the Neuroform™ and Neuroform EZ™ stents. A new kind of 
open-cell stent, the Neuroform™ Atlas, has also been applied for assisted embolism in 
vessel lumens sized between 2-4.5 mm. 
Despite complete occlusions occurring less frequently in stented aneurysms 
immediately following the procedure, the complete occlusion rate increases to 73.4% 
at the follow-up angiogram, compared to 54.0% for the no-stent group[75]. Angiographic 
recurrence occurs in 14.9% of aneurysms after stent assisted coiling compared with 
33.5% for coiling-only aneurysms[76]. Stent insertion is also likely to cause in-stent 
stenosis approximately 3.5% of the time, but most are asymptomatic[77]. However, 
permanent neurological procedure-related complications occurred more often in 
procedures with stents than without stents (7.4% vs. 3.8%)[76]. Compared with the 
balloon remodeling technique, other important factors have to be taken into 
consideration when using a stent, especially the necessity of antiplatelet therapy, which 
brings inherent risks of intracranial bleeding as well as delayed in-stent stenosis and 






































































Figure 4. Two different kinds of stent-assisted coiling techniques for aneurysm 
treatment: jailed coiling and trans-cell coiling[10b] 
3.3.2 Covered stent for aneurysm 
A more ideal approach to aneurysm treatment is to shift the treatment target from the 
aneurysm sac to the diseased parent artery for histological healing of aneurysm. 
Immediate occlusion promotes thrombus formation, which may in turn further reduce 
the hemorrhage rate caused by maneuvering within the aneurysm sac. Overlapping 
deployment of two or three bare stents and flow diverter devices can encourage flow 
diversion, but these devices cannot fully realize immediate occlusion of an aneurysm. 
Covered stents, however, can both completely occlude the aneurysm sac and keep the 
parent artery patent; furthermore, covered stents can greatly reduce the hemorrhage rate 
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complex aneurysms such as pseudo-aneurysms, wide aneurysms and large or giant 
aneurysms. Until recently, the only covered stents available were coronary stents like 
Jostent (Abbott Vascular, Redwood City, Calif) and Symbiot (Boston Scientific). In 
2002, Islak et al. reported the use of a coronary covered stent to treat giant and fusiform 
aneurysms[78]. In 2004, Saatci et al. reported using a coronary stent to treat twenty-five 
intracranial aneurysms, of which only eight patients had experienced transient 
endoleaks, which were all handled by post balloon dilation[79]. No recurrence was found 
during angiographic follow up. However, the coronary stent system has not been widely 
adopted since they are very stiff, lacking in longitudinal flexibility, and challenging to 
navigate. Moreover, they cannot easily adapt to the extreme curves of the intracranial 
vasculature and can cause damage to the vessel during stent deployment. The WillisTM 
covered stent improves on coronary stents in different aspects for intracranial 
applications, including stent structure, membrane thickness and the delivery system. 
These improvements work together to expand the flexibility of the system and to ease 
its passage through the tortuous intracranial vasculature. This new kind of intracranial 
covered stent graft has been used for the treatment of recurrent aneurysm[80], large or 
giant aneurysm[61] and carotid-cavernous sinus fistula (CCF)[81]. The 3-5 year 
angiographic follow-up revealed that 87.2% were completely occluded[10c]. 
3.3.3 Stenting for atherosclerotic stenosis 
Arteriosclerotic vascular disease is a specific form of arteriosclerosis where the 
artery wall thickens along with the invasion and accumulation of foam cells and the 
proliferation of intimal smooth-muscle cells. These physiological processes can cause 
lumen stenosis or even occlusion. In the US, according to Banerjee’s statistics, acute 
ischemic infarctions from intracranial atherosclerotic disease account for about 9~17% 
of strokes each year[82]. Balloon dilation and/or stent insertion can restructure the 
diseased lumen to allow sufficient blood flow for the brain tissue and prevent distal 
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percutaneous transluminal angioplasty (PTA) in intracranial vessels in 1980. By using 
coronary angioplasty catheters after surgical exposure of the vertebral artery at its V3 
segment, they successfully dilated high-grade basilar artery atherosclerotic stenotic 
lesions in two patients who had severe symptoms that were progressing despite 
anticoagulant therapy[83]. Since their report, PTA and stent insertion (PTAS) has been 
applied more frequently for atherosclerotic stenosis treatment in selected patients with 
extracranial and intracranial arteries[84]. Since the use of a stent led to better 
angiographic results, less chance of arterial wall dissection, distal embolism, and lower 
restenosis rate, stent insertion is gradually considered as superior to PTA alone for 
cerebral artery stenotic diseases. Stents used in intracranial arteries are often self-
expanding, either closed-cell or open-cell, and they are made of various metallic 
materials, but mainly nitinol. Most observational and retrospective single center reports 
show positive results until the SAMMPRIS trial results were first published[55b, 56b]. The 
SAMMPRIS study, a randomized controlled trial (RCT), compared treatment outcomes 
with or without stenting for patients with severe (70%–99%) symptomatic stenosis of 
a major intracranial artery[66]. Unfortunately, this study was aborted at an early stage 
after only 451 of the planned 764 patients, because at 30 days, a significantly higher 
rate of stroke and death (14.7%) was observed in the stented patients compared to the 
patients who received aggressive medical therapy alone (5.8%). This failed study drove 
the FDA to reduce the recommendations for Wingspan stent usage to patients who had 
had two or more recurrent strokes despite intensive dual antiplatelet medication and 
risk factor corrections. Meanwhile, the Vitesse Intracranial Stent Study for Ischemic 
Stroke Therapy (VISSIT) trial, another multicenter and prospective RCT, was initiated 
with the goal of evaluating the placement of a Pharos Vitesse balloon-expandable stent 
to treat intracranial stenosis in patients with cerebral or retinal ischemia symptoms. This 
study was also stopped early, after 112 of the intended 250 patients had enrolled. Again, 
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the first 30 days (24.1%) compared to those who only received medical therapy 
(9.4%)[85]. So far, there is still no significant evidence to show that intracranial stenting 
is more effective than aggressive medication when it comes to preventing strokes in 
patients with intracranial stenosis. However, some important criticisms of the 
SAMMPRIS trial cannot be ignored, including the lack of operator experience, 
treatment in an acute setting following stroke, no strict selection of patients who failed 
intensive medical therapy, stroke caused by perforator occlusion instead of low 
perfusion, and stenting in high-risk perforator rich areas. Further research with 
improved design is required to objectively evaluate intracranial stenting for 
arteriosclerotic vascular disease. In addition, procedure related complications can be 
decreased by conducting the necessary systematic training. The China Angioplasty and 
Stenting for Symptomatic Intracranial Severe Stenosis (CASSISS) trial is a new 
ongoing prospective multicenter RCT that overcomes the shortcomings of previous 
RCTs and aims to redefine the role of stenting in selected patients with symptomatic 
intracranial arterial stenosis[86]. Intracranial PTAS may further be proven to be safe and 
effective if refinements in patient and device selection or technique innovation occur in 
future studies. 
 
4. Flow diverter devices 
4.1 Overview 
Flow diverter devices (FDDs) are breakthrough inventions for intracranial 
aneurysm treatment. The concept developed from the use of overlapping traditional 
stents to obstruct cerebral aneurysms without placing any coils[87]. Since their first 
application in 2007, FDDs have evolved as endoluminal approaches in the management 
of intracranial aneurysms[53t]. This relatively new method is now rapidly becoming the 
first-line treatment modality for numerous complex cerebral aneurysms since large 
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of such devices, multiple kinds of flow diverters have been ratified for clinical use. To 
support future device development, it is necessary to review the mechanisms that are 
responsible for aneurysm closure, the stent design, the delivery of stents, and the stent 
material[89]. 
Flow diversion involves placement of a semipermeable stent to reshape the parent 
artery and direct blood flow away from the aneurysm neck while maintaining natural 
flow through the parent vessel. The efficacy of flow diverters greatly depends on their 
hemodynamic diversion causing flow stasis within the aneurysm sac leading to gradual 
thrombosis, which eventually results in occlusion of aneurysm[90]. Computational 
hemodynamics studies show that FDDs do attenuate the peak and mean kinetic energy 
of blood entering the aneurysm. An overall metal coverage rate of 30-50% in FDDs can 
reduce the maximum flow velocity at the aneurysm neck by about 80%[91]. In some 
cases, however, an FDD may generate varying mesh density over the aneurysm orifice 
during deployment and create inconsistent patterns of intra-aneurysmal flow[92]. FDDs 
further promote thrombus formation because once activated platelets pass through the 
mesh, they have a long residence time in the aneurysm[93]. The stent material itself can 
also trigger thrombus formation; small fibrin- and platelet-rich thrombi can be detected 
at the FDD surface before any observable thrombus forms in the aneurysm[94]. In 
parallel, endothelial cells can creep along the FDD surface to occlude the aneurysm 
neck over 6-12 months[95]. However, a recent study showed that until the aneurysm is 
completely sealed, there is a risk of the thrombus escaping out of the aneurysm with 
blood flow[96]. Most FFDs are comprised of microfilaments between 30 to 35 μm, and 
their pore size typically varies between 110 to 250 μm. These characteristics allow 
small perforators, with a diameter of 100 μm, to still provide sufficient (>55%) blood 
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4.2 Typical Intra-luminal flow diverters 
4.2.1 Pipeline embolization device  
4.2.1.1 PED:  
The pipeline embolization device (PED; ev3/Covidien, Irvine, CA, USA) is a flexible 
self-expanding, braided cylindrical device that consists of 48 individual strands made 
of 25 % platinum, 8% tungsten and 75% nickel-cobalt-chromium alloy. It comes in 
diameters between 2.5 to 5.0 mm, and in lengths between 10 to 35 mm. The devices 
have a pore size of 0.020-0.052 mm2 with porosity of 65-70% at its nominal 
diameter[53t]. The device is loaded in a delivery sheath and delivered through a 0.027 
inch microcatheter, where it is compressed and elongated to 2.5 times its nominal length. 
The delivery wire extends 15 mm distal to the PED and sometimes requires a clockwise 
turn to release the PED distal end. Forward pressure from the delivery wire allows the 
PED to expand and appose the vessel wall. Multiple PEDs can be telescoped over each 
other by delivery wire recapture after the previous PED is fully deployed. When a PED 
is deployed in a vessel less than 2 mm in size, the stent pores may become larger[98g]. 
(Figure 5)  
 
Figure 5. Photos and schematics of fabricated stent sheets. (a) mesh of the Enterprise 
stent, (b) mesh of the Silk stent, (c) mesh of the Pipeline FDD, (d,e) mesh of new stent 
design A and B. (f) Flow velocity inside an aneurysm by CFD simulation at T = 2.0 and 






































































4.2.1.2 PED Flex:  
Delivery and deployment of the PED Flex is the same as for the first-generation PED. 
However, several major modifications have been implemented in the Pipeline Flex: 1) 
two polytetrafluoroethylene (PTFE) flaps that can rotate 180° were added to the 
proximal side of the device to facilitate opening and resheathing the device when less 
than 90% has been deployed; 2) the laser-cut delivery wire is a noticeably stiffer 
hypotube than its predecessor with improved pushability and device responsiveness; 3) 
the distal end of the device is no longer constrained on a capture coil and thus it doesn`t 
require any torque to release the device after an initial partial release; 4) the distal tip 
coil is now 0.012 inches in diameter, compared to 0.014 inches in the first generation, 
and has a tip angle of 55°[98b]. 
The stiffer delivery wire of the PED Flex is also designed to facilitate retracting the 
microcatheter through the PED after deployment. However, failure to recapture the 
delivery wire after deployment of the device has been reported, which then requires 
removal of the delivery wire directly from the lumen of the device[98c]. 
Robust intracranial support is required for deployment of the PED Flex. The 
traditionally-used Marksman microcatheter often fails to provide sufficient support for 
delivery, deployment or resheathing of the device, particularly in cases of tortuosity. 
However, the VIA27 microcatheter is reported to provide excellent support for 
successful PED Flex delivery during procedure[98i]. Since the Pipeline Flex can be more 
precisely deployed than the first generation device, fewer devices are needed per case 
on average[98b]. 
4.2.1.3 Pipeline Shield 
The third generation Pipeline Flex Embolization Device with Shield Technology 
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polymer (thickness <3 nm) is covalently bonded to its strands to potentially reduce 
thrombogenicity and the required dose of antithrombotic medication. It has a similar 
thrombogenicity to devices like Solitaire AB (Covidien-Medtronic, Irvine, California, 
USA) and LEO plus (Balt Extrusion, Montmorency, France) stents. The Pipeline Shield 
was approved for clinical application in 2015[98d]. To date, experimental research has 
demonstrated that the Pipeline Shield reduces platelet specific thrombogenicity 
compared with the FRED flow diverter, another device used in similar cases [98h]. They 
also reported a high technical success rate of device insertion (98%). The average 
number of Pipeline Shield devices used was 1.1±0.27 devices per case, comparable to 
the Pipeline Flex[107]. The delivery system has not been updated from the previous 
generation device. 
4.2.2 Silk flow diverter 
The Silk flow diverter device (Silk, Balt Extrusion, Montmorency, France) is a braided 
device comprised of 48 nickel-titanium and 4 platinum microfilaments around 35 μm 
each. It is a closed-cell mesh cylinder with flared ends that provides 35-55 % metal 
coverage at its nominal diameter, with a pore size between 110 to 250 μm[108]. 
The Silk delivery wire has a 9 mm distal radiopaque tip. The device is deployed via a 
Vasco 21 (Balt Extrusion, Montmorency, France) microcatheter (0.0236 inch inner 
diameter) by carefully applying pressure on the delivery wire. Like the PED Flex, an 
advantage of the Silk device is that it can be resheathed and repositioned up until 90 % 
deployment[99c]. The successful deployment rate ranges between 75% and 96% (mean 
88.6%)[99b]. Silk flow diverters come in 2-5 mm diameters and 15-40 mm lengths. 
4.2.3 Surpass flow diverter 
The Surpass flow diverter device (Stryker Neurovascular, Fremont, CA, USA) is a 
single-layer, self-expanding, tube-shaped, braided mesh stent. It has a porosity of 70 % 
(metal coverage rate 30%) and high pore density of 21-32 pores/mm2, with rhomboid 
shaped pores. The device is available 2.5-5 mm in diameters and 10-35 mm in 
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numbers of strands: the 2.5 mm device has 48 strands, the 3 and 4 mm devices have 72 
strands, and the 5 mm device has 96 strands. Twelve marker wires of platinum and 
tungsten wires are used for radiopacity and the rest are made of cobalt-chromium 
material. By increasing the strand number in larger devices, the pore configuration, 
porosity and pore density are all maintained, which should reduce the requirement of 
additional device implantation[100]. The Surpass devices foreshorten upon deployment 
depending on their diameter; 3 mm, 4 mm, and 5 mm diameter devices shorten by 38% 
42% and 26%, respectively. The delivery of these devices requires a minimum 
microcatheter inner diameter of 0.040 inches, which is larger than the Pipeline device 
requirement of 0.027 inches. Because of its size, the Surpass device is not constrained 
at its delivery push wire, instead its pusher accommodates a standard 0.014-inch 
microwire. Furthermore, although deployment of the larger device is more difficult, the 
delivery system is more stable and allows for precise device placement.  
4.2.4 Flow Redirection Endoluminal Device System 
   The flow redirection endoluminal device system (FRED; MicroVention, Tustin, CA, 
USA) is a newer type of paired-stent flow diversion device with a closed-cell design. 
FRED has a unique stent-in-a-stent design; the outer stent, made of 16 woven nitinol 
wires, has a high radial force that encourages stent opening while the inner stent is 
composed of 48 braided nitinol strands that make a low-porosity mesh and create a flow 
diverting effect. This design means that FRED behaves much more like laser cut stents, 
with markedly less foreshortening[101d]. Redirection and attenuation of blood flow are 
also improved with its 16+48 wires. Taken together, the dual-layer design may provide 
potential advantages in scaffolding functions, stability, deliverability and occlusion of 
aneurysms. Currently, the FRED is available in 3.5, 4.0, 4.5, 5.0, and 5.5 mm diameters 
with a working length ranging from 7 to 56 mm. 
The dual-layer design is localized only to the main tubular body and covers about 
80% of its total length. The ends of the outer layer are flared approximately 3 mm on 
each side marked by 4 radiopaque and serve as landing zones during deployment while 
preserving side branches. An interwoven double helix of tantalum marker strands is 
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The FRED is contracted onto a 0.027-inch delivery push microwire with a radiopaque 
distal tip and can be resheathed after up to 80% deployment[101c]. A recent study 
suggested that its higher radial force may let deployment much more easier in certain 
cases[101b]. However, reports have also been made of the hydrophilic coating scraping 
off for FRED or its delivery catheter[101a].  
4.2.5 Tubridge 
The Tubridge flow diverter, developed by MicroPort Medical Company (Shanghai, 
China), is a self-expandable, low-porosity, flow-diverting mesh device with flared ends. 
Preliminary evidence supports its clinical safety and efficacy for the treatment of 
complex aneurysms. The size of Tubridge devices ranges from 2.5 to 6.5 mm in 
diameter and 12 to 45 mm in length[102]. 
Previous studies have reported two kinds of Tubridge devices. Large Tubridge devices 
(diameter ≥ 3.5 mm) are braided using 62 nickel-titanium microfilaments and 2 
platinum-iridium radioopaque microfilaments while the small Tubridge devices 
(diameter <3.5 mm) are a braid of 46 nitinol microfilaments and 2 platinum-iridium 
microfilaments. Tubridge flow diverters have a metal coverage rate between 30% and 
35% when fully deployed and are designed with a gradient in pore size, in which the 
smallest cell is only 0.040-0.050 mm2 in the middle of the device[53v]. The flared ends 
with lower metal coverage are designed to avoid perforator infarction and stent 
migration during deployment. 
 4.2.6 p64 Flow Modulation Device 
    The p64 flow modulation device (Phenox, Bochum, Germany) is a fully 
resheathable, braided tubular implant with controlled mechanical detachment. It is 
composed of 64 nitinol wires with 2 platinum radiopaque marker wires wrapped around 
its length. The device can be repositioned or withdrawn until obtaining a satisfactory 
position, even after completing deployment, a significant advantage[53w]. 
    Wires of the p64 device are grouped into bundles of 8 wires at the proximal end 
with radio-opaque 0.5-mm markers attached to the end of each bundle. The bundles are 
attached to a slotted crown shape at the end of a 180 cm stainless steel delivery wire. 
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device to prevent unexpected detachment. The device is compatible with a 0.027-inch 
internal diameter microcatheter. The deployment of p64 is similar to traditional stent 
release, which fully expands the device through a combination of pushing the delivery 
wire and retrieving the microcatheter. While the p64 is available with and without a 
distal wire, the distal wire design may increase flexibility and support during delivery 
and deployment. The porosity of p64 is relatively low, varying from 51% to 60% at 
nominal diameters, with a radial force similar to that of the PED Flex[103b]. 
A report showed that the success rate of P64 device placement ranges from 85%-
98%. The stiffness of the implant and its friction within the delivery catheter are the 
main causes of technical failure[103a]. The P64 device is available between sizes of 2.5-
5 mm in diameter with 0.5 mm increment and 9-36 mm length with 3 mm increment. 
4.2.7 Thin Film Nitinol Flow-Diversion 
    In 2009, an animal study demonstrated that pore density (number of pores/mm2), 
rather than porosity (metal-free area/total area), was an important factor to predict the 
efficacy of flow-diverting devices. Devices with a high pore density are thought to be 
more effective[110]. In contrast to other flow-diverter devices, the flow diverters based 
on Thin Film Nitinol (TFN) technology attain a very high pore density (70 pores/mm2) 
but maintain a similar metal coverage rate. TFN Flow-Diversion (NeuroSigma, Los 
Angeles, California) has a cylindrical TFN micro-mesh that is attached on a laser-cut 
nitinol stent. The TFN metal sheets are approximately 5 μm thick can be produced in 
various patterns using techniques commonly used in the microelectronics industry. This 
device enables high rates of aneurysm occlusion soon after implantation (2 weeks), as 
observed in preclinical testing[111]. 
    Meanwhile, microfabricated TFN membranes show an extreme mechanical 
bendability (up to 180°) and radial stretchability (>500%) compared with other kinds 
of flow diverters. However, after the TFN flow-diverter is compressed into a delivery 
catheter, the TFN membrane undergoes an extreme deformation of 400-500%, which 
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4.3 Typical intra-saccular flow diverters 
Intra-saccular flow diverter devices represent a different flow diversion approach in 
which the braided device redirects blood flow at the aneurysm neck after its deployment 
within the aneurysm sac. These devices are designed to treat bifurcation aneurysms.  
4.3.1 Woven EndoBridge device 
    The Woven EndoBridge device (WEB, Sequent Medical, Aliso Viejo, California, 
USA) was first marketed in 2011. It is composed of a braided nitinol wire that holds 
the device in a globular shape. WEB provides a neck metal coverage between 35% and 
45% and yields a “stent-like” adherence to the inside of the aneurysm sac[104b]. 
    The WEB device has three subtypes: the WEB Single Layer (SL) and WEB Single 
Layer Sphere (SLS) are both single layer devices made of braided nitinol/platinum 
wires while the WEB Double Layer (DL) is a mesh sphere made of two layers of 
braided nitinol wires. The device is available in sizes ranging from 4×3 mm and 11×9 
mm, and is attached to a flexible delivery wire[113]. Proximal, distal and/or middle 
radiopaque platinum markers are used to facilitate accurate positioning of the device, 
which is delivered through a 0.027 inch microcatheter and detached electrothermally. 
The device is fully retrievable.  
    More recently, Asnafi et al. performed a meta-analysis of 588 aneurysms (22% 
ruptured aneurysms) in 565 patients treated with the WEB device. Treatment failure 
occurred in 3% of all cases. The initial complete occlusion rate was 59%, and increased 
to 85% after 7 months[104a]. Furthermore, the WEB device does not require dual 
antiplatelet therapy. 
4.3.2 The Luna AES device 
   The Luna aneurysm embolization device (AES; NFocus Neuromedical, Palo Alto, 
California) is a self-expandable, braided ovoid device made from two layers of nitinol 
wire mesh. Similar to the WEB device, it is designed to disrupt flow from within the 
aneurysm, and similarly, there is no need for dual antiplatelet therapy. The device can 
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4.3.3 Medina embolization device 
The Medina embolization device (MED, Medtronic, Irvine, California, USA) is also 
designed to be an intra-saccular self-expanding flow diverter, consisting of a core wire 
and memory alloy outer filaments that are shaped into petals along the axis of the 
structure. As the device is deployed, the three-dimensional filament petal deforms to 
fill the aneurysm sac and ostium, creating a spherical shape basket and distributing the 
forces on the aneurysm wall. The MED is delivered via a smaller 0.021 inch 
microcatheter. During its deployment within the aneurysm sac it can be easily 
resheathed, redeployed and finally mechanically detached. This happens in a very 
similar manner as coil manipulation.  
   The MED potentially has the following advantages over the WEB device: 1) the 
delivery microcatheter has a smaller profile (0.021 inch ID for MED vs. 0.027 inch ID 
for WEB), which makes arrival at the target lesion and entry into the aneurysm sac 
easier; 2) the ability to place multiple MEDs in a Russian doll fashion or standard coils 
into the aneurysm is likely to cause an increase of packing density rate and earlier 
aneurysmal occlusion as compared to WEB device. An extremely rapid occlusion of 
large aneurysms has already reported in early clinical experience[53q]. 
4.3.4 Neck-bridging device 
The eCLIPs Bifurcation Remodelling System (eCLIPs, eVasc Neurovascular 
Enterprises ULC, eVasc Medical Systems Corp, Vancouver, Canada) device is a self-
expanding, nickel-titanium, fully retrievable, hemi-stent. The device has a leaf segment 
with moveable ribs, which can immediately disrupt flow in the aneurysm, while also 
allowing the placement of detachable coils, thus reducing the chance of aneurysm 
recurrence. The high density of the leaf segment, 23%-42% metal coverage, also 
provides a scaffold for endothelial cell creeping and progressive neointimal growth to 
achieve histological repair at the aneurysm neck[114]. 
4.4 Clinical applications 
The safety and efficacy of flow-diverting devices have been demonstrated in several 
well-designed trials and numerous clinical studies. Initially, the Pipeline for Uncoilable 
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large and giant wide-necked internal carotid artery aneurysms, and reported a high rate 
of complete occlusion (78 out of 108, 73.6%) with a low 5.6% rate of major stroke or 
neurologic death at 180 days. The technique success rate was 99%[115]. In 2016, the 3-
year angiographic follow-up results from the PUFS cohort showed a progressive 
complete aneurysm obliteration (93.4% cure rate) without delayed aneurysm 
recanalization and/or growth[116]. Even more recently, the five-year results of PUFS 
trial presented a 95.2% (60/63) rate of aneurysm occlusion. Moreover, no new serious 
device-related events or recanalization were observed[98e]. In the International 
Retrospective Study of PED (IntrePED) trial, the largest study on PED for cerebral 
aneurysms, Kallmes et al. reported on the safety of PED for the treatment of 906 
aneurysms in 793 patients, and showed that the neurologic morbidity and mortality rate 
was 8.4%[88]. Similarly, the prospective Aneurysm Study of Pipeline in an 
Observational Registry (ASPIRe) reported a combined neurological 
morbidity/mortality rate of 6.8% (13/191) for patients with unruptured cerebral 
aneurysms treated with PED, and the complete occlusion rate was 74.8% (77/103) 8 
months later[117]. 
Similar results are obtained with other commonly used FDDs. A multicenter 
experience from 24 centers reported that the permanent neurologic morbidity and 
mortality rates were 6% and 2.7%, respectively, in 186 intracranial aneurysms that 
received a Surpass flow diverter treatment. Of these, 75% of patients had 100% 
occlusion after a single Surpass device implant[94]. For posterior circulation complex 
aneurysms, a German multicenter study reported a complete aneurysm occlusion rate 
of 66% with the Surpass flow diverter[118]. 
The most recent experience of 4 Spanish centers of 157 patients treated with a SILK 
flow-diverter device showed total morbidity and mortality rates of 9.6% (15/157) and 
3.2% (5/157), respectively, at six months after treatment. Complete occlusion was 
observed in 78.1% (100/128) of cases within one year of the procedure[99b]. However, 
it is possible that the different designs of flow-diverter devices may slightly influence 
the rate of complications and occlusions[119]. 
Others studies have also reported safety and efficacy experiences using off-label PED 
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7 mm)[122]. However, the indications of FDD for IA treatment need to be fully defined 
and these kinds of devices have not yet to be shown to be beneficial for all type of 
patients with cerebral aneurysms. The Flow Diversion in the Treatment of Intracranial 
Aneurysm Trial (FIAT) trial, conducted in 3 Canadian hospitals, showed that a 
significantly higher proportion of patients were dead or dependent at 3 or more months 
when randomized to flow diversion. Based on those results, the authors concluded that 
FFDs were not as safe and effective as they had originally hypothesized[123]. Currently, 
the FIAT trial continues to enroll patients for whom flow diversion appears promising. 
Clinicians should be judicious when offering patients this novel and promising 
treatment option. Other trials on flow diversion have already been designed[124] since 
further intensive research needs to be conducted to clarify its clinical efficacy in highly 
selected patients. 
5. Thrombectomy devices 
5.1 Overview 
Stroke is currently the most common cause of permanent disability and the third most 
common cause of death in the world, and it is estimated that about 5.7 million people 
die of strokes each year[125]. The FDA has approved several devices for mechanical 
thrombectomy to treat acute ischemic stroke (AIS), such as stent retrievers that allow 
for mechanical thrombectomy at the site of occlusion to immediately restore blood 
flow[126]. As opposed to suction devices, stent retrievers are deployed inside the clot to 
entrap it by exerting continuous radial force on the clot to embed it into the meshed 
network, which facilitates clot retrieval. The retention force on the clot by the device is 
determined by the stent struts that embed and encase the thrombus[127]. These devices 
combine the advantages of temporary reperfusion of the affected territory and 
mechanical thrombectomy[128]. The first generation of stent retriever devices (Merci) 
was approved by FDA in 2004. Since then, the most popular stent retrievers used in 
clinic are the Solitaire FR revascularization device (EV3 Neurovascular, Irvine, 
California) and Trevo Provue Retrieval System (Stryker Neurovascular, Kalamazoo, 
Michigan). Meanwhile, many other promising devices are undergoing clinical trials to 


































































Submitted to  
54 
 





















































5 helical tapered 










































































































to provide real 
time procedural 
feedback 




















cell geometry that 
maximizes 
entrapment and 
designed to treat 
occlusions in 




































































































































tapered distal end 
























tapered distal end 





































































nitinol wire cages 









Yes 1.7 Fr NA AIS 
79.4%-
86% 






































































5.2 Typical thrombectomy devices 
5.2.1 Merci device 
The Merci clot retrieval device (Concentric Medical, Mountain View, CA) is the first 
FDA cleared embolectomy device for removing clot in AIS patients. It achieved a 69.5% 
vessel recanalization rate with adjuvant intra-arterial recombinant tissue plasminogen 
activator (rtPA) usage[129b]. The Merci Retrieval System includes the Merci retriever 
device, a microcatheter, and a balloon guide catheter.  
The first generation of the nitinol retriever device (models X4, X5 and X6) is a 
flexible shape-memory wire with 5 helical tapered coil loops at the distal end in a 
corkscrew shape. The diameter of its distal loops taper from 2.7 mm to 1.1 mm. The 
device is covered with platinum to improve visibility under fluoroscopy. The X6 is 
slightly stiffer than the X5. The Merci X series are available in 2.5, 3.0 and 3.5 mm 
diameters and are inserted through a 2.4F Merci microcatheter[136]. Once deployed 
distally to the clot, the device takes on its natural corkscrew shape to ensnare and extract 
the clot into the Merci balloon catheter, which is placed in the cervical segment of the 
internal carotid artery.  
    The L series and V series devices were later introduced in 2006 and 2008, 
respectively. The Merci second-generation L-series (L4, L5, and L6) devices were 
redesigned into a non-tapering helical nitinol coil with additional arched prolene 
filaments from the distal to the proximal end of the helix to increase clot entrapment. 
The cylindrical helix coil-like design enables optimal vessel wall apposition, and it is 
at a 90-degree angle with respect to the proximal catheter. The third generation V-series 
(V 2.0, V 2.5, and V 3.0) device is a hybrid design of the earlier two series. The V 
retrievers have a linear, non-angular design with a slight distal narrowing, but it is also 
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is delivered through a Merci microcatheter 18L. Merci devices with a loop diameter of 
2.0 mm are intended for more distal vessels (M2 segment of MCA), 2.5 mm for 
moderately sized vessels (M1 segment of MCA, vertebral artery), and 3.0 mm for large 
vessels (ICA, basilar artery)[137]. 
One disadvantage of the Merci Retriever is that the curved loops can unwind and 
slide through the clot rather than tightly engaging the target thrombus during pull 
back[138]. Despites differences in design, recanalization rates have not been reported to 
substantially differ between generations of these retriever devices[129b]. However, 
according to the SWIFT and TREVO 2 trials, the Solitaire and Trevo devices 
introduced next both achieve better blood flow recanalization than the Merci device[132b, 
133b]. 
5.2.2 Solitaire FR device 
The Solitaire stent retriever (CE marked since July 2009) is the most regularly used 
device in recent thrombectomy trials. The device is a laser-cut, self-expandable nitinol 
stent with an electrically detachable, closed cell design. It is cut from a nitinol sheet 
into a honeycomb pattern with constant cell dimensions of 2.6 × 4.5 mm. The device 
has a folded architecture of circumferentially overlapping struts with a longitudinal split 
section, which engages and pushes the clot against the vessel wall, with multiple planes 
of contact [139]. 
Currently, four sizes of devices are available: 4 mm diameter with 15 mm or 20 mm 
working lengths, and 6 mm diameter with 20 mm or 30 mm working lengths. The 
Solitaire FR 6 mm at any length has a larger radial force than the FR 4 mm. As the 
working length of Solitaire FR increases, the contact area with the vessel wall also 
increases[140]. In general, the working length should be at least the length of the 
thrombus. 
  This device is delivered by a 0.021 to 0.027 inch microcatheter via a 180 cm long, 
0.016 inch nitinol pusher wire[141]. The recommended vessel diameter is 2-4 mm for the 
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5.2.3 Trevo device 
The Trevo Retriever (Stryker Neurovascular, Mountain View, CA) is a self-
expanding, laser cut, hydrophilic coated, closed-cell nitinol stent-like retriever 
thrombectomy device which was approved in Europe in 2010. Clinical trials in US first 
enrolled patients in 2011[133b]. 
The distal end has a 4 mm soft and floppy radiopaque tip wire that allows stable 
deployment and enhances fluoroscopic visualization. The distal end is tapered over a 
distance of 10 mm, which provides a smooth transition from the radiopaque tip to the 
active area, which has higher radial force; the taper facilitates release of the device into 
more distal and smaller vessels[53ai]. Like other retrieval devices, this device is also 
deployed by unsheathing the microcatheter, leaving the device directly in the thrombus 
and allowing it to immediately begin expanding and incorporating into the thrombus. 
This passive stent opening process may help attenuate potential vascular injury. Its 
structural design also evenly distributes the radial force of the whole device throughout 
the many stent struts along the device length[133b]. Flattened stent struts oriented 
orthogonally to the device promote clot incorporation[142]. The device is permanently 
attached to a flexible 0.018-inch pusher wire that is 180 cm at the proximal end with a 
taper transition to 75 cm, which effectively prevents any accidental detachment while 
pulling back. The overall length of the Trevo device is 44 mm, with a working length 
of 20 mm and a diameter of 4 mm. Each Trevo device can be used in 1.5 to 3.5 mm 
vessels for a maximum of six retrievals[143]. 
5.2.3.1 Trevo ProVue Retriever 
The Trevo ProVue is a fully radiopaque version of the Trevo device that was released 
in November 2012[53ai]. The newer generation Trevo device is also constructed of a 
cylindrical nitinol hypotube with wide cells oriented in a helical way. Platinum is 
incorporated throughout the entire retriever structure. This fully structurally radiopaque 
design enables the operator to visualize strut compression in images, which reflects the 
progress of clot integration. Furthermore, the strut behavior may indicate the stiffness 
of the clot, or whether there may have been an underlying stenosis[144]. Like the original 
Trevo, this device also has a perpendicular strut orientation, which, in theory, should 
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    This device is 4 × 40 mm with a working length of 20 mm. It is recommended for 
use in intracranial vessels with a diameter between 1.5 mm to 4 mm and the device 
requires the use of a 0.021 inch or larger microcatheter[141]. 
5.2.3.2 Trevo XP ProVue Retriever 
The Trevo XP ProVue 3×20 mm device (Baby Trevo) is the newest generation of the 
Trevo devices. It is specifically built to retrieve clots from smaller intracranial vessels 
and has a 36 mm total length that includes a 20 mm clot capture area (working length) 
and a 3 mm diameter.  
    According to the manufacturer, the Baby Trevo should have a lower radial force 
than previous models (0.00600 N/mm compared with 0.01480 N/mm), which is 
supposed to minimize endothelial and arterial wall damage, especially in vessels of 
smaller caliber (≤ 3 mm)[132c, 145]. However, clot retriever efficacy is directly 
proportional to the radial force, so the higher radial force Solitaire device may have a 
theoretical advantage over the Baby Trevo design by enabling immediate recanalization 
upon deployment[146]. An optimized platinum alignment in the device allows for more 
efficient compression within the catheter to facilitate smooth delivery while a larger 
cell area improves embolus integration[144]. Bench test results showed that the Baby 
Trevo can provide much larger cell sizes than the Trevo device when deployed in small 
vessels. Cell size was 217% larger when deployed in a 2 mm vessel and 57% larger in 
a 3 mm vessel than 4×20 mm Trevo device[53aj, 134]. 
  The updated design removes the distal tip and taper of the ProVue Retriever. These 
design improvements decrease the length of the device that needs to be placed distally 
to the clot. Its distal end is softer than that of the Solitaire FR 4×20 mm by at least 48%, 
and the short landing zone may be beneficial while passing through or releasing 
tortuous anatomies, vessel bifurcations or in small caliber vessels. The stent retriever is 
fully radiopaque, with one proximal and two distal radiopaque markers to facilitate 
accurate positioning. It can be delivered through a small 0.017 inch microcatheter[134]. 
The device has a total length of 190 cm, and pusher wire has been narrowed to 0.015 
inch to make it compatible with smaller microcatheters than the original device and 
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5.2.4 Revive device 
The Revive device (Codman, Raynham, Massachusetts, USA) is a self-expanding, non-
detachable nitinol stent for intracranial thrombectomy. The distal end of this stent has 
an innovative closed-ended basket with smaller cells to enhance capture of clots and 
large fragments. 
    The Revive device has various cell shapes that spiral around the longitudinal axis 
of the stent. Additionally, it has a high radial force and decreasing cell size from the 
proximal to the distal retrieval zone. The basket design is optimized for centering within 
the vessel lumen and preventing further distal embolization during deployment and 
retrieval. Once device positioned across the occlusion, the displaced clot engages with 
the basket and is then retracted into the guiding catheter under simultaneous aspiration. 
    Its narrow and tall strut design provides better penetration and engagement with 
clots. However, a previous study suggests that the small cell size may be the reason for 
weak clot engagement between the filaments[142]. The stent only has one size (4.5 x 22 
mm) and is can be delivered by 0.021 or 0.027 inch inner diameter microcatheters[53n]. 
The single size design is compatible with most segments of the MCA or Vertebrobasilar 
artery; however, it is too small to be used in the distal ICA. 
5.2.5 Embolus Retriever with Interlinked Cages device 
The tubular design of typical stent retriever devices has a risk of clot fragmentation, 
migration or distal embolism. Additionally, a large contact area of metal retriever with 
the vessel wall may lead to endothelial injuries and/or vessel wall vasospasm during 
retraction[147]. The Embolus Retriever with Interlinked Cages (ERIC, MicroVention, 
Tustin, California) device is a new stent retriever designed to overcome these 
challenges[135]. Depending on the size, it consists of 3–5 spherical nitinol wire cages 
that are linked together in a linear array specifically for reducing clot fragmentation and 
distal emboli. Meanwhile, the limited vessel wall contact areas may reduce vascular 
damage.  
    ERIC is also designed for immediate thrombus retrieval with little or no delay, 
while other stent retrievers require a 3-5 minute wait for clot integration[53p]. The device 
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3 to 5. The available working lengths range from 15 mm to 44 mm. ERIC can be 
delivered through a low profile 0.017 inch microcatheter regardless of the device size 
used. The recanalization rate reported for ERIC is about 80% to 85%[53p]. 
5.3 Clinical applications 
Acute ischemic stroke is a major cause of death or disability worldwide. Intravenous 
recombinant tissue plasminogen activator (rtPA) treatments for occlusion of 
intracranial large vessels often have a low recanalization rate, with only 10% to 15% of 
ICA occlusions and 25% to 50% of proximal MCA occlusions recanalized, and only 
35% to 40% of patients achieving good clinical functional independence outcomes[148]. 
Mechanical treatment approaches for acute ischemic stroke aim for fast and efficient 
reperfusion with short procedure times. After placing a femoral artery sheath, a 
microcatheter is then inserted into the intracranial vessels and passed through the 
occlusion segment with the support of a guidewire. After using contrast injection to 
confirm its arrival at the distal normal vessel lumen, mechanical thrombectomy devices 
can be introduced via microcatheters, advanced to the affected artery, and then 
deployed under fluoroscopic guidance. Thrombectomy can be performed with or 
without proximal balloon occlusion to reduce the risk of distal embolization during the 
procedure. 
The first generation of thrombectomy devices approved by FDA were the Merci and 
Penumbra (aspiration catheter) devices. These devices had differing mechanisms to 
remove clots: (1) the Merci device is a coil-shaped retriever that can be delivered within 
the microcatheter as a wire to engage and bind the clot before being pulled back through 
the guiding catheter along with the thrombus; (2) the Penumbra system is a catheter 
aspiration device that applies suction to remove the thrombus. The Interventional 
Management of Stroke (IMS) III trial compared IV rtPA with mechanical 
thrombectomy; 45% of the included patients received clot removal using the Merci or 
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long-term functional outcome between IV rtPA and mechanical thrombectomy 
treatments. Both sub-groups also had a similar mortality rate at 90 days and a similar 
proportion of patients with symptomatic intracerebral hemorrhage. The Intra-arterial 
Versus Systemic Thrombolysis for Acute Ischemic Stroke (SYNTHESIS 
EXPANSION) trial randomized 362 patients with acute ischemic stroke into either a 
standard IV rtPA group (n=181) or a mechanical thrombectomy or intra-arterial therapy 
group (n=181) within 4.5 hours of symptom onset. In this trial, no benefit of 
endovascular therapy was observed when comparing primary outcomes (vessel 
recanalization), survival without disability at 90 days, symptomatic intracranial 
hemorrhage, and mortality[149]. Thus, early trials using first-generation devices failed to 
show any clinical benefit to acute stroke patients with regard to mortality and morbidity 
improvement despite successful recanalization rates in the technique itself. Possible 
reasons for the discrepancy include: 1) Merci or Penumbra devices were still not able 
to promise a high rate of recanalization; 2) no strict image selection such as computed 
tomographic angiography (CTA) or computed tomographic perfusion (CTP) was 
performed to confirm large vessel occlusion or to identify areas of hyper-perfusion or 
any collateral circulation compensation; 3) the study did not strictly follow the rule of 
“time is brain” to select recanalization patients and did not strictly control the time from 
symptom onset to reperfusion.  
Recently published randomized clinical trials revealed that catheter-based 
thrombectomy using retrievable stents significantly improves therapeutic outcomes for 
patients with large vessel occlusion compared to IV rtPA alone[126f, 150]. The key 
attribute for success identified in the recent clinical trials is their fast reperfusion time. 
The time from the onset of symptoms to vessel reperfusion averaged from 4.0 hours to 
5.5 hours. Clinical success can also be ascribed to the application of stent retriever 
devices. In most randomized, multi-center clinical trials, the Solitaire stent was the most 
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Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN) trial, which 
didn’t specify a particular type of stent to use, the proportion of patients who receive a 
thrombectomy using the Solitaire stent in the Endovascular Treatment for Small Core 
and Anterior Circulation Proximal Occlusion with Emphasis on Minimizing CT to 
Recanalization Times (ESCAPE), the Randomized Trial of Revascularization with 
Solitaire FR® Device vs. Best Medical Therapy in the Treatment of Acute Stroke Due 
to Anterior Circulation Large Vessel Occlusion Presenting within Eight-Hours of 
Symptom Onset (REVASCAT), Solitaire™ FR With the Intention For Thrombectomy 
as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) and 
Extending the Time for Thrombolysis in Emergency Neurological Deficits-Intra-
Arterial (EXTEND-IA) trials were 76.9%, 100%, 100% and 100% respectively. The 
total thrombectomy technique success rate can reach up to 72-100% and grade 2 or 3 
reperfusion of Thrombolysis in cerebral infarction (TICI) was achieved in 79.6-94.3% 
of occlusions, while the symptomatic intracranial hemorrhage rate was only 0-6.4%. At 
the 90-day follow up, the rate of good modified Rankin scores of 0-2 was between 53%-
71%. The TREVO device is the second most popular stent retriever device used for 
thrombectomy in clinic. The Trevo versus Merci retrievers for Thrombectomy 
Revascularisation of Large Vessel Occlusions in Acute Ischaemic Stroke (TREVO 2) 
clinical trial revealed that the technique recanalization rate for Trevo device is 86%, 
and the 90-day good outcome rate with a modified Rankin score 0-2 was 40%, with a 
symptomatic intracranial hemorrhage rate of 7%, which is slightly higher than the 
Solitaire stent[133b]. The recently-published DWI or CTP Assessment with Clinical 
Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing 
Neurointervention with Trevo (DAWN) and The Endovascular Therapy Following 
Imaging Evaluation for Ischemic Stroke (DEFUSE-3) studies found that if the clinical 
symptom-infarction or hyperperfusion-infarction areas are mismatched, patients can 
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independence rate at 90 days compared with 13% to 17% in the control group, where 
thrombectomy was performed between 6-16 or 6-24 hours after the onset of ischemic 
stroke[151]. The REVIVE SE Device is the latest marketed thrombectomy devices and 
it permits a better and faster recanalization in patient with a stroke. The REVIVE SE 
Device is designed to ease navigation through small diameter or tortuous intracranial 
vessels. Presently, several clinical trials are still being undertaken to fully investigate 
its efficacy and safety for clinical application. In 2011, Rohde et al. were the first to 
report that all lesions were successfully recanalized in 10 patients with acute large 
vessel occlusions who received the Revive device treatment. However, two patients had 
symptomatic intracranial hemorrhage and one of them was fatal[53n]. Overall, 
thrombectomy using stent retriever devices has already evolved as a standard technical 
for the treatment of acute ischemia stroke in strictly selected patients with anterior large 
vessel occlusions in clinic. 
 
6. Biosafety for metal device insertion in cerebrovasculature 
6.1 Overview 
Biosafety is one of the most important issues that needs to be fully investigated after 
metal device insertion. Device related biosafety can be divided into immediate and 
long-term stages based on its different insertion periods. The immediate biosafety stage 
(from immediately post-insertion to a few days after) is mainly affected by the device 
insertion procedure, and the typical risks include arterial wall spasms, thrombosis, distal 
embolism or side branch occlusion. Chances of their occurrence greatly depend on the 
inserted device’s mechanical properties, including passing performance, flexibility, and 
the amount of dilation in the vessel lumen. More importantly, proper device selection 
by the operators will minimize the immediate risks. Generally speaking, the better the 


































































Submitted to  
65 
 
geometry, the less damage is caused by its delivery and insertion. Long-term biosafety 
mainly depends on the body response or biocompatibility of the metal material. 
Considering that metal devices have already been widely used in clinic for a long time, 
their biological response has been proved stable in most cases. However, the local 
disease environment may contribute to the devices’ long-term biosafety. 
Endothelization is a standard way to judge if the metal device has become completely 
incorporated into the natural vasculature; any delayed endothelization exposes the 
device surface and increases the risks of thrombosis or intima over-proliferation, which 
can cause lumen restenosis[152]. 
6.1 Spasm 
Cerebral vasospasm is defined as the narrowing of the major cerebral arteries following 
subarachnoid hemorrhage caused by aneurysm rupture, arteriovenous malformation 
rupture, or brain tumor resection[153]. Vasospasm is detected in 67% of patients with 
subarachnoid hemorrhage (SAH) and is a major cause of morbidity and mortality[154]. 
Vasospasm has a biphasic course after SAH. The acute phase typically begins 3 to 4 
hours after hemorrhage begins, and often rapidly or spontaneously resolves after 
hemorrhage stops. Then, the chronic phase begins 3 to 5 days later and resolves after 
about 14 days, with maximum narrowing typically occurring between days 6 and 8[155]. 
Besides cerebral vasospasm caused by a natural history of the disease, mechanical 
stimulation caused by device insertion can induce cerebral vasospasm in intra- or extra-
cranial arteries whether or not a patient has SAH. Cerebral artery catheterization, 
balloon dilation, and stent insertion, especially when stent needs to be repositioned in 
the arterial lumen, are all capable of causing damage to the vessel wall that induces 
vasospasm. Vasospasm caused by device insertion belongs to the acute phase of 
response as it typically begins within minutes. Stent retriever devices have been 
confirmed to induce severe vasospasm due to vascular injury and autopsy studies have 
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numbers of neutrophils and neutrophil invasion into the internal elastic lamina[156]. 
Possible vasospasm mechanisms following SAH have already been well-studied. The 
central event of vasospasm is medial vascular smooth muscle contraction caused by an 
increased concentration of intracellular calcium and activated calmodulin and myosin 
light chain kinase (MLCK). Catecholamines, which can be degraded by Catechol-O-
methyltransferase (COMT) were also found to promote acute vasospasm following 
SAH[157]. Furthermore, SAH leads to increased phosphorylation of endothelial nitric 
oxide synthase (eNOS), an enzyme that synthesizes NO and plays a protective role 
against vasospasm; phosphorylation decreases NO availability and increases 
superoxide production, which may deplete residual NO even more by further reacting 
to form peroxynitrite[158]. Inflammation is often considered a factor associated with the 
chronic stage of vasospasm. For example, elevated levels of matrix-metalloproteinase-
9 (MMP-9) and VEGF following an inflammation reaction are associated with 
vasospasm[159]. These results were all obtained from studies of vasospasm following 
SAH; however, mechanical injury to arterial walls caused by device insertion might 
induce vasospasm by different mechanisms and further investigation is needed.  
Since vasospasm related to metal device implantation has a higher occurrence rate in 
SAH patients, triple “H” therapy (hypertension, hypervolemia, hemodilution) is basic 
conservative treatment to prevent or reduce its occurrence rate in SAH patients. 
Meanwhile, intra-arterial or intravenous injection of vasodilators, like papaverine, 
magnesium sulfate, erythropoietin, fasudil hydrochloride, endothelin-1 antagonists, 
nitric oxide progenitors, sildenafil and nimodipine are currently employed to manage 
device- and/or SAH-related vasospasm[160]. However, for high risk vasospasm, such as 
vasospasm occurring immediately after stent insertion or stent retriever push, there is a 
high chance of inducing thrombosis if the vasospasm is not resolved immediately. In 
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6.2 Thrombosis or thromboembolism 
Thrombosis or thromboembolism related to device insertion describes the presence of 
a thrombus or clot that originated in the device and/or fell off into distal vessel lumen. 
As an exogenetic transplant, metal device insertion into cerebral arteries has the 
problem of blood compatibility. Thus, patients are required to receive dual antiplatelet 
aggregation or anticoagulant therapy to reduce their risk of thrombosis or 
thromboembolic events. However, patients who have aspirin or clopidogrel resistance 
or who are in a hypercoagulable state may have a higher risk of induced thrombosis 
within devices.  
Thrombosis or thromboembolic events can be triggered by the metallic device, or its 
polymer or drug coatings, varying from benign reactions to excessive inflammation and 
in-device thrombosis. Depending on when it occurs, thrombosis can be categorized into 
early (<30 days), late (>30 days) and very late (>1 year) stages, and early 
thromboembolic events can be further categorized into intraprocedural (during the 
procedure) and subacute (from the end of the procedure to 30 days thereafter)[162]. The 
one-month cumulative incidence of stent thrombosis ranges from 0.4% to 5%[163]. 
However, over 80.0% of angiographically confirmed thromboembolic events occur 
within 2 days of the procedure[164]. After 30 days, the risk reduces for bare metal stent 
due to complete endothelialization within this period of time[165]. 
Diabetes, chronic kidney disease, hypercoagulable status, small vessels, multiple 
stents, bifurcation lesions and chronic total occlusion are all potential risk factors for 
thromboembolic events[166]. Device factors affecting thromboembolic event may 
include: 1) characteristics of the device, as its structural design might influence the risk 
of platelet activation after deployment. Higher metal coverage rates, closed cell designs, 
and balloon expandable deployment methods can increase the risk of thrombosis or 
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expandable release via microcatheter may reduce the risk. Functional material drug 
elution coatings or covering material may also increase the risk of thrombosis or 
thromboembolism. A previous study suggested that both the polymer coating and the 
medication it contains might influence the propensity for thrombosis[167]. 2) Anatomic 
characteristics of cerebral arteries, including their smaller vessel diameter, tortuous 
shape and arterial wall injuries such as thrombus-containing lesions and dissections[168] 
may also increase the risk of thrombosis in the lumen of the segment implanted with a 
device. 3) In some circumstances, device manipulation, such as using a stent retriever 
device, can cause arterial wall damage and induce thrombosis via the extrinsic 
coagulation pathway. 
Basic drugs including dual antiplatelet therapy and anticoagulant therapy are the 
essential treatments to prevent thromboembolic events. Antiplatelet agents such as GP 
IIb/IIIa inhibitors play an important role during treatment of thrombosis, as GP IIb/IIIa 
inhibitor application, either intravenously or intraarterially, is associated with increased 
reperfusion and decreased recurrence of stent thromboembolism. Both experimental 
and human autopsy data have revealed that thrombi within the stent contain very little 
fibrin and instead consist of mostly platelets[169]. This fact provides a strong argument 
for treatment with GP IIb/IIIa inhibitors. Some studies show the reperfusion success 
rate can reach up to around 90% when IIb/IIIa inhibitors are used along with mechanical 
recanalization[170]. Moreover, the use of GP IIb/IIIa inhibitors is the only known 
predictor that decreases the recurrence of in-stent thrombosis after an initially 
successful recanalization treatment[171]. 
Thrombolytic drugs can directly be applied to dissolve thrombi, and urokinase and 
rtPA are two of the most frequently used thrombolytic drugs. They are applied via 
catheter thrombolysis during interventional procedures. However, considering the low 
rate of fibrin in the stent thrombi, thrombolytic drugs often not very effective at 
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required and this method includes the use of guide wire mechanical fragmentation, 
catheter suction, balloon dilation and stent retrievers. For in situ thrombosis within the 
implanted devices, guide wire mechanical fragmentation and balloon dilation are often 
applied, and care should be taken to avoid further damage to the arterial wall, which 
might result in thrombus aggravation. Meanwhile, catheter suction or stent retriever 
methods are often considered for distal vessel thromboembolism. After restoration of 
antegrade blood flow, combination therapy with thrombolytic drugs or GP IIb/IIIa 
inhibitors may prompt residual thrombolysis or prevent thrombus recurrence.  
 
6. 3 Side branch occlusions 
One of the anatomic characteristics of the cerebral artery is its multiple perforator 
vessels or side branches. These perforator vessels or side branches are ending feeder 
vessels and once occluded, a brain infarction is likely to occur. After metal devices 
insertion, vessel wall contact with a high metal coverage or materials coating the 
outside of the device (as in covered stents), arterial dissection or tearing, and thrombus 
migration can all cause occlusion of perforator vessels or side branches leading to 
ischemic stroke. As the metal coverage rate of a conventional stent is only 6-8%, its 
insertion does not need to consider coverage of perforator or side branches. However, 
for flow diverters, whose metal coverage goes up to 45-70%, and for covered stents, 
whose coating material can cover the whole segment of stented artery, the risk of 
occluding perforator vessels or side branches runs much higher. 
Generally, PEDs are recommended to be inserted into cerebral arteries with branches 
or perforators. The PED device has a unique risk profile that includes occlusion of both 
side branches and perforator vessels. Side branch occlusion has been reported at a 
particularly high rate at the ophthalmic artery[172]. Another study detected no immediate 
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angiographic follow-up (mean 10 months, range 3–34.7 months) revealed 13 (15.8%) 
arterial side branches that were occluded out of 82 cases, including 2 anterior cerebral 
arteries, 8 ophthalmic arteries, and 3 posterior communicating arteries. However, no 
anterior choroidal artery occlusion was observed and no neurological symptoms were 
experienced in patients with branch occlusions [173]. 
The main issue with the covered stent usage in the cerebrovasculature is the possible 
blockage of side branches or perforating arteries due to the stented segment. Thus, 
covered stents are mostly not considered for intracranial vessels because distal cerebral 
arteries (like middle cerebral artery or basilar artery) have many perforating branches, 
which means they run a high risk of ischemia after a covered stent deployment. Such 
stents can, however, be successfully used to treat intracranial aneurysms located at the 
ICA or VA. Another reason they are not use intracranially may be that the stiffness of 
the covered stent system may not allow it to arrive at distal cerebral arteries. Instead, 
for vessels at the skull, covered stents can be applied if coverage of important side 
branches can be avoided. Important side branches like the anterior choroidal artery, the 
posterior communicating artery, the fetal type posterior cerebral artery, the anterior and 
posterior inferior cerebellar arteries and the primary trigeminal artery should not be 
covered[174]. In a previous study, covering the ophthalmic artery in one patient resulted 
in acute vision loss, which might be due to insufficient compensation of lateral branches 
by the ipsilateral external carotid artery[175]. If the ophthalmic artery or posterior 
communicating artery is suspected to be covered, caution is advised when performing 
a balloon occlusion test at the coverage segment. 
 
6.4 Endothelization, Neointima and Restenosis  
Metal devices inserted into a vessel lumen, such as a stent or flow diver device, will 
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hyperplasia refers to thickening of arterial walls due to the migration and proliferation 
of vascular smooth muscle cells (SMCs), primarily in the media or tunica intima, before 
endothelization completes. During endothelization, endothelial cells gradually creep 
and cover the metal struts, which inhibits platelet and leukocyte activation and 
maintains vascular SMCs in a nonproliferative state[176]. Active substances in the vessel 
such as NO and prostagtandin (PGI) are secreted by endothelial cells to regulate and 
maintain the balance of vessel contraction and dilation, and the coagulative and 
fibrinolytic systems, as well as control cell proliferation and inflammation reactions. 
Thus, complete endothelization has a close relationship to biosafety with regards to 
metal device insertion.  
6.4.1 Problems of neointimal hyperplasia and restenosis 
If the inserted devices have a low metal coverage rate and cause little damage to the 
vessel wall, then neointima proliferation is often mild with a quick normal 
endothelization and will run a low risk of causing intra-luminal restenosis. However, if 
the metal devices have a high metal coverage rate and induce severe damage to arterial 
wall, such as endothelial cell denudation, atherosclerotic plaque disruption, arterial wall 
dissection, and even stretching of the entire artery, then excessive neointimal 
hyperplasia or restenosis can occur. Post angioplasty restenosis is thought to mainly be 
caused by vascular smooth muscle cell (VSMC) migration and proliferation and 
excessive extracellular matrix production. Other possible reasons include elastic recoil 
of the vessel, negative remodeling or contraction, and thrombus formation at the site of 
injury[177]. In addition, VSMC over-proliferation and migration thickens arterial walls 
and decreases arterial lumen space[178]. The in-stent stenosis rate (ISR) is classified into 
four types based on the length of restenosis compared to the stented arterial length: (i) 
focal restenosis no more than 10 mm in length, (ii) diffuse lesions with more than 10 
mm of restenosis within the stent, (iii) proliferative restenosis more than 10 mm in 
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the stent[179]. These criteria are adopted from the coronary stent standards. Considering 
that the brain vasculature has its own histological features like underdeveloped SMC in 
the media and different lengths of stented arteries, ISR classifications focused on the 
cerebro vasculature to be further developed.  
Device-related restenosis or neointimal over-proliferation can be influenced by the 
following factors:  
1) Device design: features that seem to have more favorable ISR rates include open 
cell structures, suitable radial force against the arterial wall, shorter device length and 
fewer implanted devices. Meanwhile, stent strut design may also impact the 
endothelization or intimal hyperplasia by altering the stream of blood flow (Figure 6). 
2) Degree of the damage to the vessel wall: intraluminal stenosis related to device 
insertion is a type of arterial wall healing response to arterial injury. VSMC 
proliferation is closely related with rupture of the internal elastic layer. Experimental 
studies of RNA extraction 30 min after arterial wall injury caused by balloon dilation 
demonstrated that as inflation pressure increases, c-fos expression, neointimal 
formation and proliferation are stimulated[180].  
3) Degree of neointimal proliferation: Such proliferation is proportional to the 
degree of injury. Metal device insertion into a normal vessel often induces mild arterial 
wall injury while for a severely stenotic artery, angioplasty by stent insertion often 
needs to dilate the diseased artery and tear the intima, media or even the entire vessel 
wall. In this situation, severe arterial wall injury often results in an aggressive repair 
reaction and over proliferation of SMCs to induce stenosis.  
4) Inflammation reaction: Vascular inflammation, neointimal proliferation, and 
restenotic obstruction at the stented lumen induced by endovascular treatment are the 
result of complex interactions between vascular cells and the dysregulation of vascular 


































































Submitted to  
73 
 
play essential roles in inflammatory response[181]. Platelet and fibrin deposition at the 
site of injury triggers expression of cell adhesion molecules that recruit leukocytes[182]. 
Leukocytes then attach to platelets through the combination of leukocyte integrin Mac-
1 (CD11b/CD18) with platelet glycoprotein Ib-alpha[183] or when fibrinogen binds with 
platelet glycoprotein IIb/IIIa[184]. Experimental and clinical studies have revealed that 
leukocyte adhesion mediated by Mac-1 and platelets is the main mechanism that results 
in vascular inflammation and restenosis after coronary stenting[185]. Sometimes the 
intensity of infiltration by the inflammatory cells can release inflammatory mediators 
and cytokines such as platelet-derived growth factor (PDGF) and transforming growth 
factor-b (TGF-b) to induce VSMC migration and proliferation [186]. Previous studies 
have already revealed that VSMCs or myofibroblasts in the neointimal migrate from 
the media or adventitia in response to PDGF[187].  
5) Anatomic and hemodynamic factors: Considering the extremely tortuous course 
of the cerebral vasculature, blood flow in the highly curved vessels often presents 
complicated hemodynamic characteristics. When a metal device is inserted into a 
curved vessel, the greater and lesser curvature sides of the vessel wall may have 
different metal coverage rate. The lesser curvature side is more likely to have higher 
metal packing or kinking, especially in open cell stents that further disturb the blood 
flow. Deformation of the inserted device in a tortuous artery also makes for unequally 
distributed radial force, which can cause differing extents of vessel wall injury and 
vessel repair that result in stenosis. The complicated hemodynamics in curved vessels 
include an asymmetrical distribution of wall shear stress which will directly affect the 
process of endothelial cell coverage and neointimal hyperplasia (Figure 7). Previous 
research indicated that in the curved vessels, the walls with greater and lesser curvature 
are subjected to higher wall shear stress; thus, the creeping of endothelial cells from 
adjacent normal arterial walls and the deposition of endothelial progenitor cells were 
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6) Disease of the arterial wall: Arterial wall atherosclerosis is another important 
factor that encourages intimal hyperplasia. The pathology of atheroselerotic plaque 
includes subintimal lipid deposition, proliferation of SMCs and deposition of ECM, so 
injury of the atheroselerotic artery caused by metal device insertion has a larger chance 
of resulting in over intimal hyperplasia and lumen stenosis. 7) Patients with a history 
of diabetes or restenosis may run a higher risk of ISR[188]. Meanwhile, patients 
displaying systemic markers of inflammation, such as midkine, have a higher risk of 
intimal hyperplasia due to macrophage accumulation caused by stent insertion[189]. 
 
Figure 6. Diagram of the biosafety issues for metal stents insertion into the arterial 







































































Figure 7. The complicated hemodynamics in curved vessels. (A) The effect of stenting 
on vascular anatomy and computational fluid dynamics analysis found good 
correlation between low WSS areas (orange lines) and the in-stent restenosis after 14 
days on histological observation. (B) Histological observation after using a covered 
sent to treat curved cervical artery aneurysm (a-c) showed at 6 months, endothelial 
cells (yellow arrows) become tightly arranged to cover the stent strut (red arrows)  (B-
d) or form a whirlpool in the curved segment (B-e), while at 12 months, the endothelial 
cells have completely matured and are arranged even more tightly (B-f)[53ag, 191] 
 
6.4.2 Mechanism of neointimal hyperplasia 
Molecular or genetic mechanisms related to neointimal hyperplasia or in-stent 
restenosis have been carefully studied since the clinical application of stent insertion. 
Both the MAPK and the cAMP-protein kinase A (PKA) signaling pathways have been 
found to inhibit intima proliferation and formation after balloon-induced injury. In 
particular, cAMP/PKA activation markedly inhibits VSMC proliferation[192]. 
Amplifying or stimulating the cAMP/PKA pathway in VSMCs at the molecular level, 
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cAMP-induced transcription through anchoring the PKA regulatory subunit to 
subcellular membranes. These biochemical reactions increase levels of p27kip1 and 
suppress not only VSMC growth in vitro but also neointimal hyperplasia in vivo[193]. 
Meanwhile, inactivating cellular ras proteins, which are key transducers of mitogenic 
signals, in balloon-injured rats significantly reduced neointima formation (by 
approximately 55%) 14 days after balloon injury[194]. (Figure 8a) 
 
Figure 8. Several aspects of the vascular response to injury. (a) Molecular mechanisms 
of vascular smooth muscle cell proliferation and selected intracellular targets for 
antiproliferative strategies[195]. (b) miRNAs expression involved in response to vascular 
injury. (+): induction; (-): inhibition; SMCs: smooth muscle cells; ECs: endothelial 
cells. (c) Schematic diagram of the VSMC cycle and its regulatory mediators[196]. CDK: 
cyclin-dependent kinase; CKI: cyclin-kinase inhibitor; G1: Gap 1; G2: Gap 2; M: 
Mitosis; S: Synthesis. 
 
MicroRNAs (miRNAs) also play a key role to regulate the pathophysiological 
processes of neointimal hyperplasia or restenosis and have largely been investigated for 
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miRNAs mediate communication between endothelial cells (ECs) and vascular SMCs, 
monocytes, pericytes, or platelets, they play an important role in modulating the 
vascular response to injury. Generally, repair induced by vascular injury may result in 
the upregulation of a certain group of miRNAs (such as miR-21, miR-146, miR-
221/222 and miR-424) and downregulation of another group of miRNAs (such as miR-
145, miR-143, miR-125 and miR-23b), which together regulate the apoptosis, 
proliferation, migration and differentiation of both SMCs and ECs. (Figure 8b) In 
humans, miR-21 is highly expressed in atherosclerotic lesions or after vascular 
injury[198]. Upregulation of miR-21 also enhances VSMC growth both in vitro and in 
vivo after vascular injury. This effect is mediated by PTEN, a tumor suppressor that is 
a direct target of miR-21. Meanwhile, the miRNA also indirectly targets Bcl-2, 
indicating that it can modulate VSMC growth through different pathways[198a]. A 
similar regulation effect is seen in miR-146a when it binds the Krüppel-like factor 4 
(KLF-4), which is a key transcription factor that regulates the phenotypic switch of 
VSMCs: they can regulate each other[199]. High expression of the miR-221/222 cluster 
has also been found to control proliferation, migration, and apoptosis in VSMCs as well 
as in ECs[200]. Since these miRNAs target p27 and p57, their overexpression results in 
excessive neointimal growth, whereas their downregulation can reduce neointima 
formation by approximately 40% in a rat model[201]. Furthermore, miR-221/222 
upregulation inhibits EC proliferation by targeting the proto-oncogene c-kit. 
Meanwhile, miR-424 exhibits a completely different way of modulating VSMC 
proliferation than other miRNAs. Despite its increased levels after injury, miR-424 
works by directly targeting cyclin D1 to cause a G1/S transition, and thus arresting 
VSMC proliferation[202]. The major modulators of SMC phenotype to maintain VSMC 
differentiation are miR-143 and miR-145, and their overexpression prevents neointimal 
hyperplasia[203]. Their expression can be upregulated by introducing a serum response 
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vascular injury, hemodynamic stress or in atherosclerotic vessels[205] promote the 
VSMCs to transition from a synthetic phenotype to a contractile phenotype. Like miR-
146a, miR-145 directly targets KLF-4, but it also interacts with KLF-5, an inhibitor of 
myocardin[203], calmodulin kinase IIδ, and several other factors involved in serum 
response factor activity[206]. By contrast, miR-143 functions mainly by targeting Elk-
1[204a]. Similar to miR-143 and miR-145, miR-195 is another modulator of VSMC 
phenotypes to prevent VSMC proliferation and migration. Overexpression of miR-195 
decreases cell proliferation and migration by downregulating Rho-GTPase Cdc42, 
FGF1, and cyclin D1[207]. 
6.4.3 Neointimal hyperplasia prevention or treatment 
Despite intimal hyperplasia after metal device insertion being an inevitable pathological 
response, different measures can be taken to minimize the response and to reduce 
restenosis risks caused by intimal hyperplasia. These methods include: 1) Modification 
of the metal surfaces with polymers. A nitinol surface using polyhedral oligomeric 
silsesquioxanes and poly(carbonate-urea) urethane can result in a nanocomposite 
polymer which has antithrombogenic, nonbiodegradable, and in situ endothelialization 
properties[208]. Surface modification of metal devices to construct a buffer layer is 
important for long-term biocompatibility. 2) Consistent anti-inflammation drug elution 
on the device surface via a polymer carrier. By releasing drugs that target VSMC 
proliferation from the polymer-coated stent struts, drug-eluting stents (DES) have very 
successfully reduced ISR in coronary arteries since they were introduced in 2002[195]. 
3) Promotion of the process of re-endothelialization. Stent strut surface modifications 
with thromboresistant biomolecules encourages the attachment of the vascular cells to 
the stent, which is the first step of endothelialization. Substantially promising bioactive 
materials include heparin, albumin, phosphorylcholine, aptamers, elastininspired 
polymers, thrombomodulin and anti-CD34 antibody[190i]. A heparin/collagen multilayer 
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endothelialization and prevents restenosis, which indicates that the combination of an 
EC-specific ligand with a suitable matrix can promote in situ endothelialization and 
may inhibit ISR. VEGF has also been proven to promote the process of 
endothelialization. VEGF can be bound on the surface of a stent by static electricity to 
stimulate EC migration and proliferation. Another method to prompt EC adhesion or 
proliferation includes integrating adhesion proteins, like collagen, fibronectin, gelatin 
and nanofibers constructed by fibrin glue, with PLLA-CL on a metal surface to simulate 
the configuration or chemical environment of the extracellular matrix. Meanwhile, a 
polypeptide such as heparin and peptides arginine-glycine-aspartic acid (RGD) can also 
have similar effect to prompt ECs migration and proliferation.  
Intracranial vessel lumen restenosis or reocclusion induced by metal device 
implantation is a clinical dilemma as no satisfactory methods exist to resolve this issue. 
For peripheral arterial restenosis, many endovascular treatments such as plain balloons, 
rotational atherectomy, brachytherapy, drug coated balloons, cutting balloons and drug 
eluting stents are optional methods associated with of less need for target lesion 
revascularization and a reduced risk major adverse events compared with treatments 
using bare metal stents[209]. However, for intracranial application, a mechanical 
treatment such as percutaneous transluminal angioplasty dilation is the most commonly 
applied treatment. Treatment outcomes are associated with vessel lumen size, length of 
ISR, vessel curvature and whether or not it was completely occluded. Surgical treatment 
is an option for the treatment of extra-cranial restenosis, as the extra-cranial artery has 
a larger diameter and an easy access path that allows direct incision to remove the metal 
device, thrombus, plaque or hyperplastic intima. Sometimes bypass surgery can also be 
used to restore blood flow reperfusion for distal vessels and brain tissues. However, 
surgical treatment for intracranial restenosis is often difficult in technique, as the small 
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its deep location in brain, for most of the diseased artery, there is no proper vessel that 
can be used for bypass surgery.  
 
7. Future directions of intracranial metal devices 
Devices based on metal materials such as platinum and nitinol alloys have been widely 
applied in the brain vasculature for the treatment of cerebrovascular diseases. Novel 
structural designs have mostly focused on enhancing device flexibility and providing 
better occlusion, isolation or reconstruction performance during treatment for vascular 
diseases. However, many challenges remain and further investigation is needed to make 
intracranial devices safer and more effective. Drug elution and 3D printing techniques 
are well-studied and have been successfully incorporated into the cardiac and peripheral 
vasculatures; such innovations also have potential value to be applied to 
cerebrovascular disease treatment[210]. 
7.1 Biodegradable metal materials for intracranial devices  
Compared to biodegradable polymers or synthetic polymers, absorbable metals 
typically have excellent stiffness and strength, and can often be made into a much 
smaller size. Thus, they are very attractive for intracranial applications. Current 
research on metals for vascular applications includes alloys based on magnesium 
(Mg)[211], iron (Fe)[212], and zinc (Zn; Zn-Mg, Zn-Al)[213]. Magnesium is generally 
considered a neuro-protective element for acute ischemic stroke. Since magnesium, 
iron, and zinc all naturally exist in the body, Mg-, Fe- or Zn-based alloys have 
demonstrated good biocompatibility and non-toxic biodegradation, and are promising 
metals for absorbable stents. Mg stents have already been applied in the treatment of 
atherosclerotic stenosis in the coronary and inferior genicular arteries[214]. The main 
limitation of bio-absorbable Mg stents is its fast degradation rate in vivo; it can only 
reliably provide mechanical support for up to 3 months. Surface modification is one 
method to increase surface corrosion resistance, which prolongs the stent degradation 
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Hydroxyhexanoate) (PHBHHx) or poly (1, 3-trimethylene carbonate) (PTMC)[215] on 
Mg alloy. In dynamic degradation tests, the speed of degradation of PHBHHx- or 
PTMC-coated Mg alloys was found to be reduced by one and three orders of magnitude 
compared to PCL-coated and bare Mg alloys, respectively. PHBHHx- or PTMC-coated 
Mg alloys also exhibited less volume loss and generated fewer corrosion products than 
PCL-coated and bare Mg alloys after 52 weeks in rats. Research also suggests that 
micro-arc oxidation can reduce the speed of Mg alloy degradation[216]. Finally, making 
new alloys that combine different proportions of Mg mixed with other metals is another 
way to tune the degradation rate and corrosion control while enhancing 
biocompatibility. Examples of such alloys include Mg ZK60 alloy (Z= Zinc, K= 
Zirconium)[217], AZ61 (A= Aluminium, Z= Zirconium)[218], ZM21(Z= Zirconium, M= 
Manganese)[219], AE21(A= Aluminium, E= Rare earth)[220], AZ31[221]. 
Other biodegradable metals such as bio-corrodible Fe scaffolds can provide longer 
term reliable mechanical support (at least 12-18 months), have a slower biodegradation 
process, and inhibit inflammation reactions compared to Mg stents[222]. A bio-
corrodible iron scaffold is produced by laser cutting a pure Fe (> 99.8%) tube into a 
design similar to a Nitinol stent under a nitrogen environment to prevent premature 
corrosion. A mid-term angiographic patient follow up study after 6-18 months indicated 
that it is a feasible technique with no significant in-stent neointimal hyperplasia or 
inflammatory reactions around the stent struts, and no iron toxicity[222a]. Corrosion of 
the iron-based stent in tissue was observed over 4 weeks[222b]. Research on Mg- or Fe-
based alloys shows mechanical characteristics equal to or higher than stainless steel, 
but their degradation speed is still an unresolved issue. A study of Mg-based alloys 
showed that their degradation rate was too fast. In contrast, Fe-based alloys have good 
mechanical performance but unsatisfactorily slow biodegradation rate. The 
introduction of Zn and its alloys in 2013 represented a breakthrough in the field of 
biodegradable metallic stents. Zn alloys, including Zn-Mg and Zn-Al, display slower 
corrosion and degradation rates of ∼0.02 mm.y-1, about half that of standard pure Mg, 
making them ideal for stent applications[223],[224]. Zn alloys are fabricated with new 
casting process: First, they are extruded at 250°C followed by homogenization at 350°C 
for 48h. Then, a Zn alloy tube with a wall thickness of 2.5 mm is made by extrusion at 
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from localized pitting to a more uniform erosion. Currently, Zn-0.5Mg seems to be the 
most ideal material for biodegradable stent, as the grain size and orientation do not 
change during the final cutting process (Table 5). 
Despite the promising research, several important issues need to be clarified before 
using biodegradable metals in the clinic. One major concern is that the Mg or Fe alloys 
do not share the self-expandable properties of nitinol alloys, so they can only be 
assembled on balloon catheters for delivery and release. This is likely to increase the 
system profile and decrease its flexibility. Furthermore, metal biodegradation and its 
end products may impart toxic effects to healthy neurons or result in distal vessel 
embolization. Lastly, the process of metal degradation is likely to cause more severe 
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Table 5. Key properties and aspects of potential non-biodegradable and biodegradable metals for medical cerebrovascular device applications 
 316L stainless Co-Cr alloys Nitinol alloys Fe alloys Mg alloys 
Radiopaque Yes Yes No No No 
Self-expandable No No Yes No No 
Radial force Good  Excellent Good  - - 
Flexibility Good Good Excellent  Good Good 
Essential trace 
element 
Yes Yes Yes Yes Yes 
Recommended 
daily intake 
- 60-350ug/day 25-35ug/day 6-20 mg 375-500 mg 
Blood serum level - 0.4 ug/L 26 ug/L 5.0-17.6 g/L 0.73-1.06 mM 
In vivo long-term 
overdose effects 
- 





Damage of lipid membranes, proteins and 
DNA; stimulus for inflammations; 
increase of free radicals 
Excessive Mg leads to nausea; reduction of 
the excitability of neuromuscular, smooth 
muscular and cardiac regions 
Effect on local pH 
during 
degradation  
Alkalescent Acidic Alkalescent Alkalescent  Alkalescent 
Corrosion mode Localized corrosion 
Mostly localized and 
piting 
Mostly localized and 
piting 








NA NA NA Fe(OH)2, α-FeO(OH), Fe3O4 
Mg(OH)2, MgO, MgCl2, (Ca1-
xMgx)10(PO4)6OH2 






































































7.2 Drug elution techniques for intracranial devices  
Devices and designs that are effective in one particular specialty can quickly inspire 
and prompt innovations in other specialties. For example, the field of 
neurointerventional surgery has been dramatically influenced by the areas of cardiac 
and peripheral intervention. At present, drug-eluting stents (DES) have been routinely 
used in coronary arteries to prevent intimal hyperplasia and restenosis. However, this 
technique may also have a bright future in intracranial applications, especially when a 
stent is inserted into arteriosclerotic arteries. Metal device insertion provides a platform 
to carry polymers that enable the continuous release of drugs. Degradation rate is an 
effective index to judge drug release performance as it can be affected by polymer itself, 
passivation, and the fabrication process[225]. A number of polymers are commonly 
considered for use, such as polylactic acid (PLA), poly-L-lactic acid (PLLA), poly-D-
lactic acid (PDLA), polyglycolic acid (PGA), polyethylene glycol (PEG) and poly(ε-
caprolactone) (PCL). However, mixtures of two polymers to make a drug carrier for 
controlled release are more frequently used. For example, devices have been developed 
using poly(d,l-lactic-co-glycolic acid) (PLGA)[226], poly-D,L-lactic acid and 
polycaprolactone (PDLLA-PCL)[227], poly (3-hydroxybutyrate-co-3-hydroxyhexanoate) 
(PHBHHx)[215b], poly(1,3-trimethylene carbonate) (PTMC)[215a], poly(ethylene glycol)-
poly(ɛ-caprolactone) (PEG-PCL)[228], and poly(vinyl alcohol)-g-PLGA (PVA-g-
PLGA)[229]. The drugs used for DESs are mainly anti-cell proliferation drugs including: 
Sirolimus (Rapamycin), Pacilitaxel, and derivatives of Sirolimus (Everolimus, 
Zotarolimus, Novolimus and Biolimus A9)[226a]. (Figure 8c) The DESs under clinical 
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Drug release Polymer material 
Degradati





BX velocity[230] Stainless steel 140 5 
Sirolimus 
(140μg/cm2) 
100% over 15 
days 
nonerodable polymers None 
TAXUS 
NIRx[231] 
Stainless steel N/A N/A Paclitaxel (1μg/cm2) 












80% over 30 
days 








85% over 60 
days 










80% over 30 
days 












Cobalt alloy 91 5.6 
Zotarolimus 
(1.6μg/mm2) 
100% after 6 
months 
BioLinx-Parylene None 





81 7 Paclitaxel (1μg/mm2) 






BuMA[239] Stainless steel 100 N/A 
Sirolimus(1.4μg/mm
2) 









100% over 30 
days 
PDLLA N/A 
BioMatrix Flex[241] Stainless steel  112 10 
BiolimusA9 
(15.6μg/mm) 
45% over 30 
days 
PDLLA 6-9 months 












80 ＜3 Myolimus (3μg/mm) 
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NOBORI[244] Stainless steel 112 10 
BiolimusA9 
(15.6μg/mm) 
45% over 30 
days 
PDLLA 6-9months 
Axxess[245] Nitinol 152 15 
BiolimusA9 
(22μg/mm) 















81 ＜3 Novolimus(5μg/mm) 

















64 9 Cobalt-Chromium 
100% over 60 
days 
PLGA 3-4months 
EXCEL[248] Stainless steel 119 15 
Sirolimus(195-
376μg) 






















BioFreedom[251] Stainless steel 112 N/A 
BiolimusA9 
(15.6μg/mm) 





  Cre8[252] 
Cobalt-
Chromium 
80 N/A Sirolimus(90μg/cm2) 





PBMA: polybutyl methacrylate; PHMA: polyhexyl methacrylate; PDLLA: poly-(D,L)-lactic acid; PLGA: polylactic-co-glycolic acid; PVA: polyvinyl alcohol; 
PVDF: polyvinylidene fluoride; PVO: polyvinyl octal; PVP: polyvinyl pyrrolidone; PLC: polymer liquid crystal; PLA: polylactic acid; PLLA: poly-L-lactic acid; 
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The first-generation of drug eluting stents, such as the Cypher DES, are often made 
with durable polymer coatings to release paclitaxel or sirolimus[226a]. (Figure 9a) The 
first-generation DES significantly reduces neointimal response, but one major limitation 
is a durable polymer remnant that causes persistent inflammatory response due to the lack 
of biocompatibility. This often results in late and very late stent thrombosis (ST) rates and 
an increased risk of late in-stent restenosis (ISR), which is considered a “late catch-up” 
phenomenon[253]. Second-generation DESs, such as zotarolimus-eluting and everolimus-
eluting stents, are designed to have improved critical components to increase safety and 
efficacy[232]. The most distinct changes between first- and second-generation DESs are 
stent frame design and polymer composition. Several studies show that a thinner stent 
frame can reduce restenosis, endothelialization and thrombogenicity[254]. Therefore, the 
stent materials transitioned from stainless steel to CoCr[233] and PtCr[234], which enable 
the fabrication of thinner stent platforms that preserve the radial strength and recoil 
properties. For example, the XIENCE V stent uses a Multi-Link Vision’s cobalt-
chromium (CoCr) stent platform coated with a thin layer of drug polymer. The 
thicknesses of the strut and polymer are 87 μm and 7.8 μm, respectively. A more 
biologically compatible polymer coating reduces the incidence of late ST; however, this 
technology is limited by the presence of a permanent polymer, which evokes 
hypersensitivity reactions, chronic inflammation and neo-atherosclerosis. 
The long-term complications of the first- and second- generation of DES are mostly 
related to permanent polymeric materials. There are several strategies in development for 
newer generation DESs, such as biodegradable polymer (BP) DESs, polymer-free (PF) 
DESs, and fully biodegradable DESs[255]. Third-generation DESs with biodegradable 
polymers, such as the BioMatrix Flex stent (Biolimus-eluting stents), have demonstrated 
less in-stent late lumen loss and neointimal response[241, 256]. Although BPs are less 
inflammatory than DPs, they still can induce an inflammatory response. Therefore, the 
fourth-generation polymer-free DESs (PF-DES) have been promoted as an ideal solution 
to this problem[251-252, 257]. The platform material of PF-DES is stainless steel with a 
microporous surface, and the anti-proliferative drug is released from the struts. Four types 
of PF-DES are currently under clinical evaluation: microporous DES, DES with reservoir 
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One alternative to permanent stent insertion, where polymers or stent struts can cause 
complications, may be to develop completely bio-resorbable vascular scaffolds (BVS). 
BVSs have some important advantages: (1) they are completely bio-resorbable, leave no 
residual materials in the vessel wall, and do not damage the integrity of the vascular 
structure, (2) sufficient mechanical flexibility to adapt to the vessel geometry, which may 
have favorable effects on blood flow[258], (3) the vasomotor and physiological function of 
the scaffold segment is regained within a few months after implantation, and (4) they 
introduce no imaging artifacts to noninvasive imaging modalities such as MR or CT 
scans[259]. Several types of materials are being investigated for BVS[225b], among which 
PLLA and magnesium are the most promising. Other materials suitable for BVS may 
include iron alloys[222a] and PLLA/PDLA/L-lactic-co-ε-caprolactone[260]. 
Drug eluting techniques have already profoundly influenced coronary heart disease 
treatment, and the use of drug-eluting stents or balloons has become the first line 
treatment to handle restenosis clinically. In cerebral artery atherosclerosis, the 
SAMMPRIS trial clearly revealed better outcomes for symptomatic intracranial stenosis 
with aggressive medical management than with percutaneous angioplasty and metallic 
stenting[66a]. As a result, metallic stents to treat intracranial stenosis should only be used 
for patients who have failed in medical therapy or who have high risk factors[66b]. 
However, the selection of patients and intervention procedures was considered to be 
deficient in the SAMMPRIS trial; thus, several additional studies have been carried out 
to determine if drug eluting stents might bring better treatment outcomes for intracranial 
atherosclerosis. Although the studies have already revealed that the restenosis rate is 
significantly reduced compared to the bare metal stent treatment, all drug eluting stents 
applied in cerebral arteries so far have been coronary stents[261]. More flexible drug 
eluting stents need to be developed to improve safety in the cerebrovasculature. Presently, 
the drug eluting technique is also being applied in flow diverters. The PED 3 flow diverter 
uses a surface modification of phosphorilcholine. These surface modified flow diverters 
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incidence rate for the classic PED is 1.72 times higher than for the Pipeline Flex with 
Shield Technology[262]. 
Nevertheless, safety is still the primary concern about applying drug eluting techniques in 
brain vasculature. Sustained release of anti-proliferation drugs carried by the metal devices 
may cause damage to neurons, and moreover, materials can fall off during stent inflation or 
drug carrier degradation, which may increase the risk of distal vessel embolization to cause 
a brain infarction. Furthermore, delayed endothelization or suppressed inflammation 
reaction by drugs runs a high risk of thrombosis and other complications (Figure 9b). 
 
Figure 9. Controlled drug releasing schematic diagram and endothelization process 
of the drug eluting stents. (a) Two-stage drug release of the polymer degradation and 
erosion. Stage 1: slow release by diffusion through the polymer; Stage 2: enhanced 
release contributed by polymer degradation and erosion. (b) Characteristic images of 
endothelial coverage were assessed by scanning electron microscopy at 1 and 2 days (A) 
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7.3 Personalized device manufacture for intracranial devices 
3D printing is becoming a new option in manufacturing to enable simultaneous 
customization and enhanced functionality. Increasingly, this technology can help satisfy 
the great need for patient-specific artificial organs, implants or devices, especially in 
surgery applications[264]. Innovation in 3D printing techniques and the development of 
multifunctional printable materials can drive the future application of 3D printing in many 
fields. Many medical devices are currently manufactured using metals and/or their alloys. 
For long-term tissue replacement therapy, they are usually designed as implants or 
fixtures to undertake loads because of their excellent strength and ductility[265]. The metals 
and their alloys that can be 3D printed for medical applications are generally: 
conventional metals and their alloys, shape memory alloys, and biodegradable metals.  
The two commonly used methods of 3D printing are Directed Energy Deposition 
(DED) and Powder Bed Fusion (PBF). The working principle of DED and PBF differs in 
one fundamental way: in DED, a continuous stream of metal powder or wire is melted by 
a high power-density laser as it is deposited onto the substrate, whereas PBF pre-deposits 
a layer of metal powder and then melts it at the desired location under a focused laser 
beam with selectively controlled thermal energy[266].. The quantity directly affects the 
printing resolution in a DED manufacturing process. Several processes have been created 
based on PBF technology, including selective laser sintering (SLS) and selective laser 
melting (SLM), direct metal laser sintering (DMLS), laser cussing and electron beam 
melting (EBM). DMLS generally uses both metal powder and a high power laser to sinter 
together a target structure, so it is an additive manufacturing (AM) or rapid prototyping 
(RP) process. This process can be used to produce dense parts, but post-treatment is often 
required to make it gas- or pressure-tight. In fact, many tradenames (laser sintering, 
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3D printed metal devices that can provide anatomically-personalized hemodynamic 
intervention treatments may have an especially bright future in the treatment of 
cerebrovascular disease[267]. Metal devices used in the brain, such as stents and flow 
diverters, especially stand to benefit from the application of 3D printing techniques. As 
each cerebral vasculature has its unique tortuous course, different patients or diseases may 
require the stent to have custom-designed 3D angles or diameters in different stent 
segments. Thus, 3D printed stents promise improved adaptation to the vascular wall to 
reduce damage to the arterial wall related to device insertion, which may in turn reduce 
the risk of thrombosis or late in-stent restenosis. Furthermore, considering that arterial 
stenosis, occlusion and aneurysms are all hemodynamics-related diseases, enhancing the 
occlusion rate of a flow diverter or the dilating strength of a stent may improve the 
treatment outcomes. 3D printing may improve the performance of these metal devices in 
the following ways: 1) Vascular stents: as intracranial stents often require both 
mechanical support and high flexibility, we can design and 3D print a patient-specific 
nitinol alloy stent with an enhanced number or thickness of the stent struts, or increase 
the diameter in the diseased artery to improve the hemodynamics after stenting; 
meanwhile, we can adjust the design for a normal artery lumen by reducing the stent 
diameter or the number or thickness of the stent to enhance its flexibility. These patient-
specific stent designs cannot be efficiently manufactured by laser cutting or weaving 
techniques[268]. 2) Flow diverters: a flow diverter at the aneurysm neck needs high metal 
coverage to produce a maximal flow re-direction, while in normal vessel lumens, the 
metal coverage should be low to maintain the patency of vessel branches. Current designs 
of flow diverters are braided using nitinol wires, so it is impossible to create different 
metal coverage rates in different stent segments, while 3D print can easily produce this 
type of design[269].  
The great advantage of 3D printing technology is that it provides easy customization 
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promises artificial organs, implants or devices that are patient-specific[270]. Although 
much progress has already been made, the future of 3D printing technology will require 
continued development in both printing technology and novel printable materials. 
 
8. Conclusion and future perspectives 
In summary, endovascular metal device insertion is already a revolutionary technology 
for the treatment of cerebral vascular diseases, including ischemic or hemorrhagic stroke. 
The wide application of this technology has made it possible to treat previously 
untreatable diseases, and promoted the transition from traditional open surgery to less 
invasive catheter-based interventions. However, some challenges remain when using 
metal devices in the cerebral vasculature. These future directions may lead to potential 
solutions to these problems:  
i) Devices used in brain vasculature often require excellent mechanical performance, 
such as high flexibility or radial force. The mechanical properties of currently available 
metal materials restrict their application in smaller or distal cerebral vasculature (with 
diameter <2mm). Thus, new metal alloys or novel structural designs must be developed 
to improve the devices’ mechanical performance and reduce their profile.  
ii) Permanent metal device insertion faces challenges of device-related acute 
thrombosis or long-term vessel lumen restenosis. Drug-eluting techniques have been 
widely applied in the coronary or peripheral vasculatures to prevent long-term lumen loss 
after stent insertion, but its safety and efficacy in intracranial vessels still needs further 
investigation. The main concerns about the safety of drug-elution technology center on 
drug neurotoxicity and risks related to the drug carrier when applied in the brain. Thus, 
further research in this area is primarily focused on the following aspects: 1) finding safer 
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to prevent device-induced complications and reduce neurotoxicity; 2) optimizing drug 
loading techniques to achieve sustained drug release while minimizing the carrier fall off 
risk. Moreover, the risk of acute thrombosis or inflammation caused by non-
biodegradable or biodegradable carriers should be fully considered.  
iii) As metal device insertion is permanent, risks like restenosis, inflammation and 
thrombus formation cannot be completely avoided. The ideal model is to have a device 
that is inserted to treat the disease, and that completely biodegrades after treatment is 
completed without further interruption to the normal vasculature. Biodegradable 
polymers or metals have already been used in the coronary or peripheral vasculatures in 
the clinic, but too-short or too-long degradation periods, degradation induced by 
inflammation response, and unsatisfactory mechanical performance are major limitations. 
Thus, further research to find more suitable biodegradable materials that have excellent 
mechanical properties and appropriate biodegradation modes is the future direction. Also 
important is to avoid distal vessel embolization or acute thrombosis during the 
biodegradation period; a combination of drug-elution techniques on biodegradable 
material surfaces may be an effective way to reduce inflammation during degradation.  
iv) In view of the unique set of anatomies, vessel lumen diameters, and vessel wall 
structures comprising the cerebral vasculature of each person, individualized devices 
require both flexibility of structure and mechanical strength. Meanwhile, flow dynamics 
and tissue response to devices are also different from person to person, so only a 
personalized device can guarantee maximized treatment outcomes and reduced 
complications. With the development of 3D printing technology, images collected from 
computed tomographic angiography (CTA), magnetic resonance angiography (MRA) or 
digital subtraction angiography (DSA) can be processed to obtain a 3D digital vessel 
model or image that can then be used to design a personalized metal device. These 
technologies will be certainly applied in clinical to enhance treatment outcomes in the 
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